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In vivo functional significance of CCAT2 long non-coding RNA in
myelodysplastic syndrome
Maitri Y. Shah, M.S.
Supervisory Professor: George A. Calin, M.D., Ph.D.
Abstract
Long non-coding RNAs form the largest part of the mammalian non-coding
transcriptome and control gene expression at various levels including chromatin
modification, transcriptional and post-transcriptional processing. Although the
underlying molecular mechanisms are not yet entirely understood, lncRNAs are
implicated in initiation and progression of several cancers. CCAT2 is a lncRNA that
spans the highly conserved 8q24 region associated with increased risk for various
cancers. CCAT2 has been shown to play an important role in inducing chromosomal
instability and supporting cell proliferation and cell cycle arrest. However, a causal
role of CCAT2 in initiation of tumorigenesis and the importance of G/T SNP in
CCAT2-induced phenotype still remains to be resolved. The purpose of this study
was to elucidate the role of CCAT2 and its specific alleles (G/T) in regulation of
cellular processes that drive tumorigenesis using a genetically engineered mouse
model. We generated transgenic mice for each CCAT2 allele using random
integration approach in C57Bl6/N background.
CCAT2(G/T)

mice

displayed

spontaneous

induction

of

widespread

pancytopenias with splenomegaly and hepatomegaly. CCAT2(G/T) BM biopsies
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displayed severe myeloid and erythroid hyperplasia with enhanced proliferation and
excessive apoptosis, along with extramedullary hematopoiesis in spleen and liver.
Percentage of HSPCs was significantly reduced in BM of these mice, with increased
presence of immature erythroid blasts and granulocyte-macrophage progenitors
suggesting a block in differentiation. HSPCs of CCAT2(G/T) mice showed increased
frequency of cytogenetic aberrations, including breaks and chromosomal fusions.
However, these mice don’t develop AML, suggesting CCAT2 is critical in initiation of
MDS. Microarray expression profiling of CCAT2(G/T) HSPCs revealed enrichment of
pathways associated with epigenetic regulation, chromosomal instability and cell
cycle regulation. We further identified significantly higher CCAT2 expression in the
MDS patients as compared to healthy volunteers. Interestingly, patients with AML
had significantly lower expression of CCAT2 as compared to patients with only MDS.
Based on these data, we conclude that CCAT2 plays an important role in
regulation of normal hematopoiesis, and its deregulation can lead to MDS. CCAT2
lncRNA can be developed into a diagnostic and prognostic marker, as well as a
novel intervention target for MDS therapy. CCAT2(G/T) mice can serve as a robust
model for studying initiation of de novo MDS and as a pre-clinical model for
evaluation of new therapies for low-risk MDS.
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CHAPTER I: Introduction

(Parts of this section were adapted with permission in part from Shah, MY and Calin, GA,
MicroRNAs as therapeutic targets in human cancers, Wiley Interdisciplinary Reviews - RNA, 5 (4),
537-548 (2014); Shah, MY and Calin, GA, Regulatory RNA, Encyclopedia of Genetics, 2013; and
Shah, MY and Calin, GA, MicroRNAs and Cancer Therapeutics, Principles of Molecular
Diagnostics and Personalized Cancer Medicine, 2012)

1

The non-coding RNA revolution
The complexity of the human genome, transcriptome and proteome
organization necessitates a robust and dynamic regulatory system that helps
facilitate the coordinated performance of each functional element. RNA molecules
have emerged as excellent candidates for this job by the virtue of their diversity and
versatility. Historically, RNA had been relegated to a secondary messenger for DNA,
conveying protein-coding instructions to diverse intracellular destinations. However,
accumulating evidence over the past decade has recognized RNA as a major player
in some of the cell’s most vital activities (Mercer et al., 2009). The large portion of
the human genome, which we only now know gets transcribed but not necessarily
translated and is usually considered the “dark matter” of the genome, represents a
hidden layer of regulation imposed by the newly identified class of regulatory RNAs.
These are a heterogeneous group of non-protein-coding RNAs (ncRNAs) that play
an important role in controlling gene activity at different levels.
From genomic analyses, it is evident that over 95% of the human
transcriptional output is from ncRNAs (Szymanski and Barciszewski, 2002). A part of
this comprises of housekeeping RNAs, such as rRNA (ribosomal RNA) and tRNA
(transfer RNA), which are constitutively expressed and are required for normal
functioning of the cells. The largest fraction consists of regulatory RNAs that help
coordinate and regulate the gene activity. Regulatory ncRNAs can be broadly
divided into two classes based on their size, small ncRNAs (less than 200bp) and

	
  

	
   2	
  

long ncRNA (longer than 200bp). Both small and long ncRNAs can then be further
categorized according to the location of their transcript origin.
Small regulatory ncRNA (sncRNA) mainly include microRNAs (miRNAs) and
silencing RNAs (siRNAs). miRNAs are small (19-24 nt), endogenous, highly
conserved ncRNAs which negatively regulate gene expression post-transcription.
miRNAs are usually transcribed by RNA polymerase II (RNAPII) as autonomous
transcription units, or as clusters from a polycistronic transcription unit which can be
located in the exonic or intronic regions of non-protein coding regions, or in the
intronic region of protein-coding transcription units (Ambros, 2004; Bartel, 2004).
miRNA biogenesis is a multi-step process involving coordinated cropping and dicing
by RNase III enzymes Drosha and Dicer to produce mature miRNA. These are
incorporated into the RISC (RNA-induced silencing complex), which then cause
gene suppression by binding at the 3’-UTR of mRNA. Endo-siRNAs are short,
endogenous, double-stranded RNA duplexes which can cause complete gene
silencing by RNA interference (RNAi) (Carthew and Sontheimer, 2009). Another
important class of sncRNAs are piRNAs (Piwi-interacting RNAs), that are transcribed
from transposable elements (TEs) and function in RNAi and related pathways in
association with Piwi proteins of the Argonaute family (Thomson and Lin, 2009).
Other functional classes of sncRNAs with limited experimental evidence include
promoter-associated short RNAs, termini-associated short RNAs, 3’-UTR derived
RNAs, splice-site RNAs, transcription start site associated RNAs, small nuclear
RNAs and small nucleolar RNAs.
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Long regulatory ncRNAs (lncRNAs) are a recently identified class of
regulatory RNAs with important implications in human diseases (Mercer et al., 2009;
Spizzo et al., 2009). They are defined as ncRNAs greater than 200 nucleotides in
length, and encompass a board spectrum of different RNA classes, including long
intergenic RNAs (formerly lincRNAs), enhancer RNAs (eRNAs), circular RNAs,
pseudogenes and sense and antisense RNAs overlapping other protein-coding or
non-coding transcripts (Xue and He, 2014). They make up the largest portion of the
human non-coding transcriptome and act through several distinct mechanisms. The
best functionally characterized are the lincRNAs (long intergenic ncRNAs), including
the most studied HOTAIR (Hox transcript antisense RNA) gene. Other lncRNAs
includes the transcribed ultraconserved regions (T-UCRs), transcripts from the
regions in the genome showing extraordinary conservation patterns across several
species. An example of T-UCRs is uc.73A, which acts as an oncogene in colon
cancer (Calin et al., 2007). Another class are single stranded antisense RNAs which
are transcribed in the opposite orientation from a protein-coding gene and are
complementary to the mRNA sequence. Antisense RNAs have been implicated in
gene silencing at the chromatin and transcriptional levels. An additional class of
lncRNAs is long intronic ncRNAs, defined based on their site of transcription (Louro
et al., 2009). These are generally cis-acting elements, which regulate the genome
locally. Recently, a new type of ncRNA transcribed from the enhancer regions,
eRNAs, have been identified which are also important in transcriptional regulation
(Orom et al., 2010). The biological context and significance of several of these noncoding transcripts still needs to be evaluated. They might play a hitherto
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unrecognized critical regulatory role in controlling gene expression in a variety of
organisms.
Widespread functionality of long- and micro-non-coding RNAs
The discovery of regulatory RNAs has greatly accelerated since the
availability of the complete human genome sequence. The broad functional
repertoire of regulatory ncRNAs makes it difficult to classify them based on their
activity. These can regulate several biological processes using a wide array of
molecular mechanisms. Majority of the regulatory ncRNAs act as cis-regulatory
elements and control the activity of the neighboring protein-coding genes (Xue and
He, 2014). However, certain RNAs also act trans-specific, controlling the activity of
genes located on different chromosome loci. This opens up the entire landscape of
the human genome for RNA-mediated regulation. However, unlike the housekeeping
RNAs, regulatory ncRNAs are expressed in tissue- and cell-specific manner,
implying a developmentally regulated mechanism of their expression. The abundant
and pervasive transcription of these ncRNAs from the human genome, but at low
levels, reinforces the functional regulatory nature of these transcripts. These RNAs
play a critical role in regulating each stage of the genetic process, from how the
information is stored, processed and transmitted.
Regulatory ncRNAs play an important role in chromatin modification and
epigenetic regulation. LncRNAs mediate epigenetic changes by recruiting histonemodifying or chromatin remodelling complexes and DNA methyltransferases to
specific gene loci (Lee, 2012). One such long ncRNA, HOTAIR, is transcribed from
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the HOXC cluster locus, and functions in trans-specific manner to silence
transcription at HOXD locus by recruiting Polycomb chromatin remodeling
complexes (Gupta et al., 2010). LncRNAs are also important in regulation of
chromatin architecture and epigenetic memory. Small regulatory RNAs, like piRNAs
have been associated with heterochromatin formation and transposon activity in
various species (Thomson and Lin, 2009). LncRNAs also play an important role in
dosage compensation by mediating X chromosome inactivation. Xist, a long ncRNA
from the Xist locus (Plath et al., 2002), and its antisense transcript, Tsix (Sado et al.,
2005), act cis-specific and together propagate the epigenetic silencing of an
individual X chromosome in women. Another phenomenon that closely resembles
dosage compensation is genetic imprinting, wherein one of the two parental alleles
of a gene gets preferentially silenced to maintain parent-of-origin-specific gene
expression (Koerner et al., 2009). In humans, the well-characterized imprinting
lncRNAs are H19 and Kcnq1ot1, which sustain silencing of the IGF2 and KCNQ1
genes on the maternal and paternal alleles respectively. Certain small ncRNAs are
also important for regulation of dosage compensation and genetic imprinting
processes (Koerner et al., 2009).
ncRNAs have been also shown to regulate gene expression at the
transcriptional level through direct and indirect mechanisms. LncRNAs interact
globally with the transcriptional machinery of the RNAPII, regulating the assembly of
initiation complex or inhibiting transcription elongation (Rinn and Chang, 2012).
Examples are Alu elements, heat shock transcripts that are transcribed in response
to stress. These bind to RNAPII and prevent formation of active pre-initiation
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complexes thus allowing for rapid gene repression in response to stress (Mariner et
al., 2008). LncRNAs also afford gene-specific transcription regulation by interacting
with specific transcription factors or by acting themselves as co-factors, enhancers
or promoters (Rinn and Chang, 2012). For example, cell-lineage-specific-factors
such as forkhead box A1 (FoxA1) have been shown to regulate the expression of
androgen receptor and reprogramming of the hormonal response by causing a
switch in the binding of the androgen receptor to certain enhancers (Yang et al.,
2013).
LncRNA can control several steps in the post-transcriptional processing of
mRNAs, including splicing, editing, transport and degradation (Wang and Chang,
2011). Post-transcriptional gene silencing is achieved mainly by small ncRNAs,
mainly miRNAs and siRNAs. miRNAs bind to the 3’-UTR of the mature mRNA to
achieve mRNA translational suppression (by imperfect complementarity) or mRNA
degradation (by perfect complementarity), thus regulating the expression of
hundreds of genes (Bartel, 2004; Carthew and Sontheimer, 2009). Similarly, siRNAs
usually target homologous sequences with perfect complementarity and cause gene
silencing via the RNAi pathway (Carthew and Sontheimer, 2009). miRNAs play an
important role in multiple biological processes, including developmental timing,
embryogenesis, cell differentiation, organogenesis, metabolism, apoptosis and
various diseases, including cancers. Few miRNAs can also promote gene
expression and activate translation under conditions of stress (Vasudevan et al.,
2007). Additionally, specific miRNAs that carry a distinct hexanucleotide terminal
motif, like miR-29b, were found enriched in the nucleus, suggesting extra miRNA
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functions in different subcellular compartments (Hwang et al., 2007). It has been
shown that miRNAs in the nucleus may act at the promoter level affecting
transcription, as exemplified by binding of miR-373 to the CDH1 promoter and
stimulating transcription (Place et al., 2008). Also, a novel function for miRNAs
called “decoy activity” was reported. Mechanistically, miR-328 interacts with hnRNPE2 and prevents its binding to the CEBPA (CCAAT/enhancer-binding protein alpha)
intercistronic mRNA region; this restores C/EBPa expression which, in turn directly
enhances miR-328 transcription (Eiring et al., 2010). Other classes of ncRNAs that
act post-transciptionally are antisense RNAs, which are involved in alternate splicing
(Mercer et al., 2009). Two cancer-associated lncRNA, MALAT1 and NEAT1, were
found to be important in RNA splicing, editing and transport (Chen and Carmichael,
2009; Tripathi et al., 2010). MALAT1 has been shown to sequester phosphorylated
serine/arginine-rich splicing factors (SRSFs), inducing alternative splicing of premRNAs (Tripathi et al., 2010).
Few lncRNAs can directly modulate protein localization and function
(Willingham et al., 2005). Similar interactions have also been reported between
lncRNAs and small ncRNAs, demonstrating an important possibility of self-regulation
by regulating RNAs. On certain occasions, mRNAs can also function at RNA level,
by inducing translation (Yoon et al., 2012). Recently, a novel biological role was
identified where mRNAs are expressed as pseudogenes, which can then regulate
coding gene expression (Johnsson et al., 2013; Karreth et al., 2011). These data
reveal an unexpected non-coding function for mRNA. Thus, regulatory RNAs act as
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a part of a larger molecular circuitry with complex, interlaced regulatory networks
that function at several levels in the human cell.
Figure 1 summarizes the various potential functions of lncRNAs that currently
identified. Depending on the cellular localization of lncRNAs, nuclear lncRNAs can
regulate transcription by acting as enhancer RNA (eRNA), for example regulation of
p53 by p53 eRNAs (Melo et al., 2013) (A), by recruiting chromatin modifying
complexes, for example regulation of PRC2 complex by HOTAIR (Gupta et al.,
2010) (B), or by regulating transcription factor activity, like by association of PANDA
lncRNA with transcription factor NF-YA (Hung et al., 2011) (C). Moreover, they can
regulate gene expression by acting on the spatial conformation of chromosomes, as
illustrated by alteration of X chromosome by Xist RNA (Plath et al., 2002) (D) or by
influencing pre-mRNA splicing, for example Malat1 co-localises with pre-mRNAsplicing factor SF2/ASF and CC3 antigen in the nuclear speckles (Bernard et al.,
2010; Tripathi et al., 2010) (E). Cytoplasmic lncRNAs can regulate mRNA
expression by regulating mRNA stability, as in the example of NEAT1 that is
involved in nuclear retention of mRNAs (Chen and Carmichael, 2009) (F), mRNA
translation as shown by neuron-specific antisense Uchl1 that specifically promotes
the translation of UCHL1 under rapamycin treatment (Carrieri et al., 2012) (G), or by
competing for microRNA binding, like the pseudogene PTENP1 that competes with
its coding counterpart, the tumor-suppressor PTEN, for a set of miRNAs (Johnsson
et al., 2013; Karreth et al., 2011) (H). In addition, few lncRNAs contain small open
reading frames (ORFs) that can be translated in biological active small peptides, as
described by Slavoff et al, 2013 (Slavoff et al., 2013) (I).
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Figure 1: Models of lncRNA functions.
The figure describes the different functional mechanisms of lncRNAs
This figure is used with permission and originally published by Morlando M, Ballarino M, Fatica A.
in Long Non-Coding RNAs: New Players in Hematopoiesis and Leukemia. Frontiers in Medicine.
2015; 2:23 (Morlando et al., 2015).
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Non-coding RNAs in cancer
Cancer represents a complex multistep genetic disorder characterized by
deregulation of homeostasis at the genomic, transcriptomic and proteomic levels
(Vogelstein and Kinzler, 2004). The preferred choice of treatment for most human
malignancies for the last century has been surgery and chemotherapy. However, the
severe toxicities, adverse side effects and the poor quality of living associated with
the chemotherapeutic treatment emphasize the need for new therapeutic
interventions for cancer patients. The major advances in the last decade have
focused on designing novel targeted therapy capable of targeting specifically the
malignant cells in a more rational way. The advent of miRNAs and lncRNAs provide
an additional layer of gene regulation on a broad spectrum of biological pathways by
fine-tuning protein expression levels. By the virtue of their ability to target multiple
protein-coding genes and their aberrant perturbations in widespread cancers,
miRNAs have emerged to be promising novel therapeutic targets and intervention
tools. With the advances in next-generation sequencing and genome wide
association studies, the next decade will make possible the therapeutic targeting of
lncRNAs. The following sections discuss the involvement of ncRNAs in cancer and
their potential application in diagnosis and treatment of cancer.
Ubiquitous ncRNA alterations in cancers
Aberrant expression of miRNA and other ncRNA levels has been implicated
in a broad spectrum of human diseases, including autoimmune, cardiovascular and
psychiatric diseases, diabetes and cancers (Trang et al., 2008). A growing body of

	
  

	
   11	
  

evidence suggests that these ncRNAs play a vital role in cancer predisposition,
initiation, maintenance, progression and metastasis (Esquela-Kerscher and Slack,
2006). miRNA expression profiling studies have identified a unique miRNA signature
profile that can differentiate normal from cancer tissues and also classify different
tumor types and grades (Calin and Croce, 2006). Recent expression studies have
identified considerable cancer-specific alterations in lncRNAs too, in tumor-specific
manner at distinct stages of cancer progression. lncRNA MALAT1 is aberrantly
overexpressed during metastasis of non-small cell lung cancer, and acts as a
prognostic

marker

for

poor

survival

(Xue

and

He,

2014).

LncRNAs

HOTAIR and HULC also exhibit strong expression level specifically in cancer (Gupta
et al., 2010; Panzitt et al., 2007).
The widespread dysregulation of ncRNAs can be explained by their frequent
location in cancer-associated hotspots of the human genome, including fragile sites,
minimal regions of amplification, loss of heterozygosity sites, and common
breakpoint regions (Calin et al., 2004). Other mechanisms of this dysregulation
include chromosomal deletions or translocations of regions with ncRNA genes,
epigenetic regulation of ncRNA expression, alterations in ncRNA promoter activity
by oncogenes and tumor suppressor genes, and presence of mutated ncRNA
structural variants (Croce, 2009).
ncRNAs function as oncogenes or tumor suppressor genes
ncRNAs including miRNAs and transcribed-ultraconserved regions (T-UCRs)
contribute to tumorigenesis by functioning as oncogenes or tumor suppressor genes
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(TSGs) (Calin et al., 2007; Croce, 2009; Esquela-Kerscher and Slack, 2006).
miRNAs that target oncogenes and whose expression is lost in most human cancers
are classified as tumor suppressor miRNAs (TSmiRs). Loss of TSmiR expression
due to somatic alterations or germline mutations can initiate or enhance
tumorigenecity. One of the important examples of TSmiRs is miR-15b/miR-16-1
cluster, which is frequently deleted in B-cell chronic lymphocytic leukemia (CLL) and
targets several oncogenes such as BCL2, CCND1 and WNT3A (Calin et al., 2008).
A knockout mouse model targeting the miR-15b/miR-16-1 cluster recapitulated the
CLL-associated phenotype, validating the in vivo functionality of these TSmiRs
(Klein et al., 2010). Other important TSmiRs are the let-7 family members, miR-29,
miR-34 family, miR-122 and miR-143/145 cluster (Croce, 2009). In contrast,
overexpressed miRNAs that promote tumorigenecity by targeting TSGs are
classified as oncomiRs (Esquela-Kerscher and Slack, 2006). One of the most
prevalent oncomiR is miR-21, which is overexpressed in almost all human cancers
and targets PTEN and PDCD4 (Asangani et al., 2008). Spontaneous tumorigenesis
in transgenic mice overexpressing miR-155 has also established miR-155 as a bona
fide oncomiR (Costinean et al., 2006). Other miRNAs with oncogenic function
include miR-17-92 cluster, miR-155, miR-200 family, miR-221/222 cluster and miR372/373 cluster (Esquela-Kerscher and Slack, 2006). Another example includes the
classic lncRNA Xist with a potent tumor suppressor effect. The deletion of Xist in the
blood compartment leads to an aggressive myeloproliferative neoplasm and
myelodysplastic syndrome in mice due to aberrant X reactivation and multiple
autosomal changes (Yildirim et al., 2013).
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ncRNAs in cancer metastasis
miRNAs and lncRNAs have also been shown to act as activators or
suppressors of tumor metastasis. One such miRNA is miR-10b, which promotes
metastasis of breast cancer to the lungs by targeting HOXD10, and thus increasing
the expression of RHOC. HOTAIR lncRNA has also been implicated in breast
cancer metastasis.
OncomiR addiction
The concept of addiction or dependency of tumor cells on activating
mutations in certain oncogenic factors for survival and proliferation has been
recently demonstrated for oncogenic miRNAs. Medina et al (Medina et al., 2010)
developed a conditional transgenic mouse overexpressing miR-21 and showed that
these mice developed spontaneous pre-B malignant lymphoid-like phenotype. In the
absence of miR-21, malignant cells undergo apoptosis and the tumors regress.
These in vivo experimental findings from transgenic mice strongly advocate the
causative role of miRNAs in carcinogenesis, and further support their use for
therapeutic intervention.
ncRNAs as biomarkers for cancer
Because of the widespread dysregulation of ncRNAs in all types of tumors,
miRNA and lncRNA expression profiling in cancer patients has been a valuable
signature classifier (Calin and Croce, 2006). The distinct ncRNA expression patterns
between the normal and cancer tissues serve as diagnostic, predictive and
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prognostic biomarkers. miRNA signatures can classify tumors of different types and
grades, and also correlate with chemotherapy and incidence of drug resistance
patterns. The recent detection of stable miRNAs in serum has opened up new
avenues for non-invasive biomarkers in cancer prognosis (Cortez et al., 2011).
‘Sponge’-based regulatory network
The recent revolutionary discovery of lncRNAs functioning as ‘sponges’
(Salmena et al., 2011) lend further support to the potential use of ncRNAs as
therapeutic agents. The sponge hypothesis states that the extensive human
transcriptome, including transcribed pseudogenes, mRNAs and lncRNAs interact or
crosstalk with each other through the miRNA responsive elements (MREs),
establishing a comprehensive intricate regulatory network. For example, tumor
suppressor PTEN is finely regulated by its ceRNAs, PTENP1 pseudogene and ZEB2
mRNA (Karreth et al., 2011; Tay et al., 2011). In the context of miRNA therapy,
miRNA modulation may have more profound manifestations in an as-yetuncharacterized RNA-dependent aspect. miRNAs that form autoregulatory loops
with other ncRNAs might undergo analogous genetic alterations in neoplasia via
similar underlying mechanisms and pathways. Thus, therapeutic modulation of
miRNA levels might shift the balance and set up a cellular cascade enabling a more
pronounced biological effect than previously anticipated. This discovery reveals a
whole new realm of therapeutic possibilities for human cancers. More research to
identify other cancer-associated sponge-RNA-miRNA networks needs to be done
before the full therapeutic potential of such regulatory loops can be exploited. The
advent of ncRNAs has expanded the arena of novel potential targets available for
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therapy. ncRNA therapy in combination with the conventional therapy might prove to
be a better therapeutic option. However, insights on the importance of lncRNAs in
human diseases are still developing. The new genomic and bioinformatic tools
should be useful in identifying the whole spectrum of ncRNAs and characterizing
their functional significance. More unbiased, focused research on the mechanistic
basis of these ncRNAs is essential to understand their potential applications in
medicine.
Figure 2 describes the lncRNAs and their putative functions in cancer. Table
1 provides a list of known lncRNAs that play a critical role in cancer pathogenesis.
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CCAT2

CCAT2

Figure 2: LncRNAs impact the hallmarks of cancer. The six hallmarks of cancer
with selected associated lncRNAs that are involved in cancer onset and progression.
This figure is used with permission and originally published by Di Gesualdo F, Capaccioli S, Lulli
M. (2014) in A pathophysiological view of the long non-coding RNA world. Oncotarget 5(22): 10976–
10996 (Di Gesualdo et al., 2014).
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Table 1: List of long non-coding RNAs with known function in cancers
lncRNA

Involvement in
cancer

Function

Refs

AIRN

Imprinting, Chromatinmediated repression,
transcription interference

hepatocellular
carcinoma

(Oliva et al., 2009)

HIF1a-AS

Messenger RNA decay

renal cancer

(Thrash-Bingham
and Tartof, 1999)

ANRIL

Chromatin-mediated
repression at the INK4b–
ARF–INK4a locus

acute
lymphoblastic
leukemia, gastric,
non-small cell
lung, prostate
cancers

(Iacobucci et al.,
2011; Nie et al.,
2015; Zhang et al.,
2014)

GAS5

Repression of
glucocorticoid receptormediated transcription

breast, kidney,
prostate cancer

HOTAIR

Chromatin-mediated
epression at the HOXD
locus

breast, gastric,
lung, colorectal
cancers

HOTTIP

Chromatin-mediated
activation at the HOXA
locus

hepatocellular,
pancreatic,
tongue squamous
cell carcinoma

HULC

Downregulation of miRNAmediated repression by
miRNA-sequesteration

colorectal,
hepatocellular
carcinoma

MALAT1

Scaffolding of subnuclear
domains

bladder, breast,
liver, lung, gastric
cancers

MEG3

regulation of p53
transcriptional activation

cervical, nonsmall cell lung,
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(MourtadaMaarabouni et al.,
2009; Pickard et
al., 2013; Qiao et
al., 2013)
(Cheng et al.,
2015; Gupta et al.,
2010; Niinuma et
al., 2012; Wu et
al., 2014b; Zhao et
al., 2014a)
(Cheng et al.,
2015; Li et al.,
2015; Quagliata et
al., 2014; Tsang et
al., 2015; Zhang et
al., 2015a)
(Du et al., 2012;
Panzitt et al.,
2007; Peng et al.,
2014; Wang et al.,
2010; Zhao et al.,
2014b)
(Ji et al., 2014;
Jiang et al., 2014;
Liu et al., 2014;
Wu et al., 2014a;
Yang et al., 2015)
(Sun et al., 2014;
Xia et al., 2015;

gastric, ovarian
cancers, pituitary
adenoma
Neuroblas
toma MYC
(NAT)
PTENP1
pseudoge
ne

TERC

XIST

	
  

Inhibition of neuroblastoma
MYC intron 1 splicing

neuroblastoma

Upregulation of PTEN by
sequestration of miRNAs

prostate cancer

Telomere template

prostate cancer

X inactivation

Breast, cervical,
ovarian,
hematological
cancers
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Yin et al., 2015)

(Krystal et al.,
1990)
(Johnsson et al.,
2013; Karreth et
al., 2011)
(Bojovic and
Crowe, 2011;
Jones et al., 2012;
Visnovsky et al.,
2014; Wang et al.,
2014)
(Kawakami et al.,
2004; Laner et al.,
2005; VincentSalomon et al.,
2007; Yildirim et
al., 2013)

CCAT2 - a novel oncogenic long non-coding RNA
Cancer-associated genomic regions (CAGR) are regions showing high
frequency of cancer related abnormalities, such as loss of heterozygosity or
amplifications (Calin et al., 2004). These have long been implicated in cancer
predisposition; however the underlying molecular mechanisms responsible for the
instability still remain a mystery. One such widely studied CAGR is the 8q24.21
genomic region that has been associated with several human cancers, including
prostate, colorectal, breast and bladder cancer (Ghoussaini et al., 2008). The region
is highly unstable, with numerous-genome wide association studies (GWAS)
mapping a large number of SNPs (single nucleotide polymorphism) to within a 1.5Mb gene-free region on this locus. One SNP of particular importance is the
rs6983267, with the G allele of the SNP conferring increased risk of colorectal,
prostate and ovarian cancers (Gruber et al., 2007; Haiman et al., 2007; Tomlinson et
al., 2007; Zanke et al., 2007). In colorectal cancer (CRC), the G allele predisposes to
colon cancer with an odds ratio of 1.27 for GT and 1.47 for GG (Haiman et al.,
2007). CRC being the second most common cause of cancer-related deaths, the
contribution of the SNP variant is significant, due to its widespread prevalence
among Caucasians (45-50%) and Africans (85%) (Haiman et al., 2007). The SNP
falls within an ultraconserved DNA enhancer region (Jia et al., 2009), regulating the
expression of the MYC gene present 335kb downstream of the SNP (Pomerantz et
al., 2009; Sotelo et al., 2010). The cancer risk allele (G) binds preferentially to the
beta-catenin-TCF4 transcription factor and activates the Wnt signaling pathway
(Tuupanen et al., 2009). However, in contradiction, the SNP does not affect the
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efficiency of interaction with the MYC gene (Wright et al., 2010). Moreover, the
Genome Wide Association Studies (GWAS) that reported the rs6983267 association
with cancer was unable to identify any linkage between rs6983267 genotype and
POU5F1P1 or MYC expression, amplification, and mutations in patient samples
(Tomlinson et al., 2007; Zanke et al., 2007). In spite of the extensive research of
several years, no known protein-coding gene and no mutation in the known proteincoding genes near this CAGR has been identified; and thus the mechanism by
which this SNP promotes CRC still remains undefined.
Our lab identified a novel 1.7-kb long non-coding transcript at this SNP locus,
called Colon Cancer Associated Transcript 2 (CCAT2) (Ling et al., 2013). CCAT2
spans the highly conserved 8q24 region and is transcribed into two novel transcripts,
CCAT2-G or CCAT2-T, based on the G/T SNP locus.
The seminal study on CCAT2 showed this lncRNA is specifically
overexpressed in microsatellite stable (MSS) CRC samples (Ling et al., 2013).
Patient data analysis showed that this lncRNA is specifically overexpressed in
microsatellite stable (MSS) CRC samples. In vitro experiments suggested that
CCAT2 increased tumor formation and metastasis, and conferred resistance to
chemotherapeutics drugs. A consistent positive correlation was observed between
CCAT2 and MYC expression both in cell line models and CRC patient samples. We
also observed a higher β-catenin expression and higher Wnt activity in CCAT2overexpressing

clones.

Finally,

exogenous

CCAT2

expression

induced

chromosomal instability (CIN) phenotype in HCT116 cells, a microsatellite-instable
(MSI) CRC cell line with CIN-negative phenotype. The high expression of CCAT2 in
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MSS CRC, the ability to enhance tumor formation and metastasis, induce CIN and
activation of Wnt pathway suggests that CCAT2 is an important oncogene in CRC
predisposition and progression.

	
  

Figure 3: CCAT2 is transcribed from the 8q24.21 genomic locus.
This figure is used with permission and originally published by Ling, H., Spizzo, R., Atlasi, Y.,
Nicoloso, M., Shimizu, M., Redis, R.S., Nishida, N., Gafa, R., Song, J., Guo, Z., et al. (2013) in
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and
chromosomal instability in colon cancer. Genome Res 23, 1446-1461 (Ling et al., 2013).
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CCAT2 lncRNA in cancer
CCAT2 is also overexpressed in breast cancer (Redis et al., 2013), non-small
cell lung cancer (Qiu et al., 2014), esophageal cancer (Wang et al., 2015b; Zhang et
al., 2015b), and gastric cancer (Wang et al., 2015a). Redis et al reported that
CCAT2 could serve as a predictive biomarker in lymph node positive (LNP) breast
cancer. For this subgroup, high levels of CCAT2 suggest the patients will not benefit
from CMF (cyclophosphamide, methotrexate and 5-fluorouracil) adjuvant
chemotherapy, with shorter metastasis-free survival and shorted overall survival.
Additionally, CCAT2 up-regulated cell migration and downregulated chemosensitivity
to 5’FU in breast cancer cell lines. These data suggest that CCAT2 plays an
oncogenic role in breast cancer patients.
The study by Qiu et al reported that CCAT2 was significantly over-expressed
in NSCLC tissues compared with paired adjacent normal tissues. Over-expression of
CCAT2 was significantly associated with lung adenocarcinoma, but not squamous
cell cancer. In vitro silencing of CCAT2 by siRNA led to inhibition of proliferation and
invasion in NSCLC cell lines. Additionally, CCAT2 could also predict lymph
metastasis in lung cancer patients when combined with carcinoembryonic
antigen test. These findings additionally confirm oncogenic role of CCAT2 in lung
adenocarcinoma.
The level of CCAT2 was positively correlated with TNM stages and positive
lymph nodes metastasis (LNM) in esophageal squamous cell carcinoma (ESCC)
(Zhang et al., 2015b). CCAT2 expression and MYC amplification were also

	
  

	
   23	
  

significantly associated with TNM stages and LNM. High CCAT2 expression and
MYC amplification were significantly associated with poorer overall survival in
ESCC patients. Additionally, (Wang et al., 2015b) showed that CCAT2 expression
level was significantly associated with smoking status.
(Wang et al., 2015a) reported that CCAT2 expression levels were significantly
higher in gastric cancer tissues than those in adjacent non-tumor tissues. It also
positively correlated with higher incidence of lymph node metastasis and metastasis.
Moreover, patients with high CCAT2 had shorter overall survival and progression-free
survival compared with the low CCAT2 group. Finally, CCAT2 expression was
identified as an independent poor prognostic factor for gastric cancer patients,
valiating its oncogenic role in gastric cancer.
CCAT2 is overexpressed in CIN positive CRC samples.
To detect the ncRNA gene transcribed in the rs6983267 conserved region,
we designed primers spanning the SNP and adjacent 50 bp in both orientations
(Figure 4A) and found a transcript that was expressed in human ovary, testis and
brain tissues (Ling et al., 2013). RACE cloning from colon cancer cDNAs identified a
~340 nt transcript (CCAT2). Northern blot analysis confirmed the existence of
CCAT2 transcript in sense orientation (data not shown). MSS CRC tumors with CIN
phenotype exhibited a significantly higher expression of CCAT2 than MSI tumors or
normal colon tissues that lacked CIN (Figure 4B). These findings suggested that
CCAT2 might be a novel long ncRNA with potential oncogenic effect.
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a	
  

b	
  

Figure 4: Transcription of CCAT2 in CRC.
A) Genomic location of CCAT2 spanning the rs6983267 conserved region;
B) CCAT2 expression in CRC patients.
This figure is used with permission and originally published by Ling, H., Spizzo, R., Atlasi, Y.,
Nicoloso, M., Shimizu, M., Redis, R.S., Nishida, N., Gafa, R., Song, J., Guo, Z., et al. (2013) in
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and
chromosomal instability in colon cancer. Genome Res 23, 1446-1461 (Ling et al., 2013).
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CCAT2 increases tumor formation and metastasis.
To check if CCAT2 had an oncogenic role, we cloned CCAT2 cDNA in a
retroviral expression vector and transfected it into the HCT116 cells, which
expressed low endogenous levels of CCAT2. Under low adherence conditions,
CCAT2-transduced cells showed increased proliferation and higher colony-forming
ability (data not shown). Consistently, subcutaneous transplantation of CCAT2overexpressing cells into Swiss nu-nu/Ncr nude mice resulted in more tumors of
larger volumes (Figure 5A).
Next, we studied the involvement of CCAT2 in promoting cancer metastasis.
In vitro migration assay showed a 2-fold increase in the migration of CCAT2transduced cells (Figure 5B). Injection of CCAT2-overexpressing cells into the
spleen of Swiss nu-nu/Ncr nude mice resulted in increased liver metastasis rate (6 of
9 mice) as well as more metastatic tumors than that found in control group mice (1 of
5 mice) (Figure 5C).. Thus, in vitro and in vivo studies confirmed the tumor
formation and metastatic potential of CCAT2.
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A	
  

B	
  

C	
  

Figure 5: CCAT2 increases tumor formation and metastasis.
A) CCAT2-overexpressing HCT116 clones increase subcutaneous tumor formation
in a mouse xenograft model compared to empty HCT116 controls;
B) HCT116 cells transduced with CCAT2 showed higher migratory ability by
migration chamber assay; and
C) CCAT2 promotes tumor metastasis in mice after intrasplenic injection of CCAT2overexpressing HCT116 clones.
This figure is used with permission and originally published by Ling, H., Spizzo, R., Atlasi, Y.,
Nicoloso, M., Shimizu, M., Redis, R.S., Nishida, N., Gafa, R., Song, J., Guo, Z., et al. (2013) in
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and
chromosomal instability in colon cancer. Genome Res 23, 1446-1461 (Ling et al., 2013).
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CCAT2 induces chromosomal instability.
MSS CRCs are characterized by their widespread CIN phenotype.
Upregulation of CCAT2 specifically in MSS CRC implied a possible involvement of
CCAT2 in CIN initiation and/or maintenance. HCT116 is an MSI CRC cell line with
near-diploid karyotype (Barber 2008). We generated stable clones of HCT116 cells
with higher ( and #8) or basal (empty and #3) CCAT2 expression. Karyotyping
analysis revealed that the percentage of cells with normal metaphase was markedly
lower in clones with high CCAT2 expression (59.5% in #2 and 31.4% in #8,
respectively) than in clones with basal CCAT2 expression (84.2% in empty and
94.3% in #3, respectively) (Figure 6A). In the same analysis, CCAT2
overexpression dramatically increased the percentage of cells with polyploidy from
5.3% (empty) and 2.8% (#3) to 33.3% and 60.0% (#8), respectively (Figure 6A).
CCAT2 also contributed to increased chromosomal exchange and greater DNA
content. Consistently, we detected a near-tetraploid status in clone #8 by spectral
karyotype analysis (data not shown). These findings were further validated by a
second batch of eight CCAT2 clones that exhibited similar numerical and structural
chromosomal aberrations (Figure 6B).
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Figure 6: CCAT2 induces chromosomal instability.
A) Increased chromosomal abnormalities in CCAT2-overexpressing clones, as
identified by genomic instability analysis;
B) CCAT2 induces chromosomal instability in a second set of CCAT2overexpressing clones.
This figure is used with permission and originally published by Ling, H., Spizzo, R., Atlasi, Y.,
Nicoloso, M., Shimizu, M., Redis, R.S., Nishida, N., Gafa, R., Song, J., Guo, Z., et al. (2013) in
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and
chromosomal instability in colon cancer. Genome Res 23, 1446-1461 (Ling et al., 2013).
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CCAT2 regulates MYC and β-catenin expression.
Since CCAT2 is transcribed from the region that acts as an enhancer to MYC
gene, we analyzed the levels of MYC in relation to CCAT2. We found higher
expression levels of MYC in cells that overexpress CCAT2 (3.4- and 2.5-fold
increase in #2 and #8 clones, respectively) (Figure 7A). To further understand the
regulation of MYC by CCAT2, we analyzed if other targets of MYC were also
regulated by CCAT2. We observed upregulation of β-catenin (data not shown) and
miRNA-17/92 cluster genes in these clones (data not shown). Conversely, downregulation of CCAT2 using shRNAs decreased MYC expression in stably transfected
COLO320 cells in a CCAT2-dependent fashion (Figure 7B). Thus, CCAT2 regulates
the transcription of MYC at RNA as well as protein levels. Additionally, we detected
that the expression of CCAT2 was dependent on TCF4 (transcription factor 4) and
Wnt pathway. However differential G vs T allele behavior was observed, with higher
TCF4-induced stimulation of CCAT2 and hence higher transcription of MYC in high
risk G allele (data not shown).
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A

B

Figure 7: CCAT2 regulates MYC and β-catenin.
A, B) Correlation of CCAT2 and MYC expression (A) and β-catenin (B) in CCAT2overexpressing HCT116 clones. CCAT2 induces the expression of MYC;
C) Downregulation of CCAT2 using shRNAs reduced MYC mRNA expression in
COLO320 cells.
This figure is used with permission and originally published by Ling, H., Spizzo, R., Atlasi, Y.,
Nicoloso, M., Shimizu, M., Redis, R.S., Nishida, N., Gafa, R., Song, J., Guo, Z., et al. (2013) in
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and
chromosomal instability in colon cancer. Genome Res 23, 1446-1461 (Ling et al., 2013).
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Hypothesis and Aims of the Study
These data indicates that CCAT2 functions as an oncogene by regulating
MYC expression and inducing chromosomal instability, thus predisposing a cell to
cancer phenotype. However, several questions regarding the exact molecular
mechanism of CCAT2-induced phenotype still remain, because it is difficult to
conclusively establish the genetic events important for tumor initiation in the artificial
milieu of the in vitro systems. A causal role of CCAT2 in initiation of tumorigenesis
and the importance of G/T SNP in CCAT2-induced phenotype still remains to be
resolved. Characterizing the role in CCAT2 in cancer initiation will help develop
CCAT2 as a diagnostic and prognostic marker. The purpose of our study was to
elucidate the role of CCAT2 and its specific alleles in regulation of cellular processes
that drive spontaneous tumorigenesis.
To do this, we established a genetically engineered mouse model
overexpressing CCAT2 in all the body tissues at clinically relevant levels. This
experimental strategy was designed to help us identify the tissue/organ most
sensitive to CCAT2 expression. During the initial study, we observed that in vivo
CCAT2 overexpression induces pancytopenia, BM insufficiency and signs of de
novo myelodysplastic syndrome (MDS).
We hypothesized that constitutive overexpression of CCAT2 induces
chromosomal instability in HSCs and inhibits maturation of immature progenitor cells
by regulating proteins important in MDS development.
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To support our hypothesis, we decided to pursue the following tasks:
Aim 1: To study the oncogenic potential of CCAT2 in initiation and
progression of MDS
Aim 2: To delineate the underlying mechanism of MDS initiation by CCAT2
Aim 3: To detect and characterize CCAT2 expression in BMCs of MDS patients
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Cell lines and culture
HEK293 and SET2 cells were obtained from the American Type Culture Collection
and validated by the Characterized Cell Line Core at The University of Texas MD
Anderson Cancer Center using STR DNA fingerprinting. Both cells were maintained
and cultured according to ATCC’s instructions. All of the cell lines are routinely
screened for Mycoplasma species (Mycoalert Mycoplasma Detection Kit, Lonza). All
in vitro and in vivo experiments were conducted when cells were 70% to 80%
confluent.
CCAT2 transgenic mice
CCAT2 (G/T) transgenic mice were generated using random integration approach. A
1.7kb human cDNA of CCAT2 expressing either the G or T allele was cloned into a
vector backbone containing the CAG promoter, along with eGFP reporter gene
followed by IRES site. Pronuclear injection of the entire 4.5kb linearized insert and
generation of founder mice was performed by the MDACC Genetically Engineered
Mouse Facility. The founders were mated with C57BL/6 mice. Pups were screened
for presence of the transgene by both PCR and Southern blot analysis on tailextracted DNA according to standard protocols. For PCR screening, three different
primer pairs were used to detect different products in the inserted transgene. Pups
showing positive detection for all three products were identified as founders.
Southern blot analysis was performed to confirm insertion of CCAT2 cassette in the
mice genome, and to determine to copy number of the insertion. The expression of
CCAT2 transcript was tested by Real time quantitative PCR with human specific set
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of primers previously described in (Ling et al., 2013). All the protocols and
experiments were conducted according to the guidelines of the MDACC Institutional
animal care and use committee.
Hematological measurements and peripheral blood morphology
Blood was collected from tail vein for hematological measurements. Peripheral blood
cell counts were performed on an Avida hematology analyzer. For morphological
assessment, peripheral blood smears were stained with Hema III stain (SigmaAldrich) for 10  min followed by rinsing in dH2O for 3  min. Images were taken using a
60× objective on a Leica microscope outfitted with a camera.
Histology and Immunohistochemistry
Mice were necropsied, and femurs, sternum, spleens, and livers were fixed in 10%
buffered formalin, included in paraffin, and then cut into 4 um sections. Sections
were stained with H&E according to standard protocols. For the dewaxing step,
sections were heated for 1hour at 55°C, followed by rehydration steps through a
graded ethanol series and distilled water, immersed in PBS, and then treated with
0.1% trypsin solution in Tris buffer for 30 min at 37°C. Endogenous peroxidase was
blocked with 10% normal serum. Ki67, CD3, CD4, and CD20 were used as primary
anti-mouse

antibodies

(BD

PharMingen).

Secondary

antibodies

and

diaminobenzidine were added according to the manufacturer’s instruction.
Cytochemical Staining
Cytospins of bone marrow cells were prepared following standard procedure, and
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fixed in methanol for 7 min. Cytochemical assays for myeloperoxidase, (Sigma),
nonspecific esterase (α-naphthyl butyrate, Sigma), periodic acid-Schiff [PAS], and
reticulin were performed according to manufacturer’s instructions.
Mouse hematopoietic progenitor assay
Methylcellulose colony formation assay (CFU-C) were performed using Methocult
GF M3434 (Stem Cell Technologies). Bone marrow and spleen cells were obtained
from CCAT2(G/T) and WT mice and red blood cells were lysed using Red blood cell
lysis solution (Sigma). 10,000 bone marrow cells or 100,000 spleen cells were plated
in duplicate. Colonies were identified and counted following 7 days culture at 37C
with 5% CO2.
RNA extraction, reverse transcription and real time qPCR
Total RNA was extracted from patient samples, mice tissues or cultured cells using
Trizol and following manufacturer’s protocol (Sigma). RNA concentrations were
measured with spectrophotometer NanoDrop ND-1000 instrument (NanoDrop
Tachnologies, Termo Scientific, Wilmington, DE, USA). Reverse transcription was
performed using random hexamers with SuperScript III Reverse Polymerase
according to manufacturer’s protocol (Invitrogen). Quantitative RT-PCR analysis was
performed with SYBR Green using specific primes (Appendix). B2M, HRPT or PGK1
were used as internal control. MicroRNA expression was tested using TaqMan
microRNA assay (Applied Biosystems). The cDNA was synthesized using TaqMan
Reverse Transcription Reagents kit (Applied Biosystems) and then used for
quantitative RT-PCR analysis with TaqMan probes and SsoFast Supermix (Bio-rad).
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Primers and probes for each miRNA were purchased from TaqMan. U6 snRNA was
used as an internal control. Experiments were performed in triplicates. Relative
expression levels were calculated using the 2-ΔΔCt method.
In situ hybridization
The FFPE tissue sections were first digested with 5 µg/mL proteinase K for 20
minutes at RT, and were then loaded onto Ventana Discovery Ultra system (Ventana
Medical Systems, Inc, Tucson, AZ) for in situ hybridization. The tissue slides were
incubated with double-DIG labeled probe for CCAT2 or control U6 (Exiqon) for 2 hrs
at 55° C. The digoxigenins were detected with a polyclonal anti-DIG antibody and
alkaline phosphatase conjugated second antibody (Ventana) using NBT-BCIP as
the substrate. The signal intensities of CCAT2 and RNU6-6P expression were
quantified by using the intensity measurement tools of the Image-Pro Plus software
package (Media Cybernetics).
Genomic instability analysis
Femur bone marrow CCAT2(G/T) or WT mice was flushed and collected with RPMI
medium 1640 + 20% FBS. BMCs were cultured overnight in complete RPMI medium
using standard methods. Cells were then exposed to Colcemid (0.04 µg/mL) for 25
min at 37°C and to hypotonic treatment (0.075 M KCl) for 20 min at room
temperature, and then were fixed in a methanol and acetic acid mixture (3:1 by
volume) for 15 min and washed three times in the fixative. The slides were air-dried,
stained in 4% Giemsa, and coded for the blind analysis. Later, the slides were
decoded for the evaluation of results. Slides were analyzed for several parameters,
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including chromosome aberrations (as evidenced by both chromosome- and
chromatid-type breaks), fragments, tetraploidy, fusions, and formation of tri-radials.
Images were captured using Cytovision Imaging system (Applied Imaging) attached
to a Nikon Eclipse 600 microscope. Twenty to thirty karyotypes were prepared from
each sample and described using the standard chromosome nomenclature for mice.
Spectral karyotyping
Spectral karyotyping was performed according to the manufacturer's protocol using
Mouse Paint probes (Applied Spectral Imaging, ASI). Images were captured using a
Nikon 600 microscope equipped with Spectral karyotyping software from ASI.
Northern blot
Total RNA was isolated using using Trizol and following manufacturer’s protocol
(Sigma). RNA samples (30 µg each) were run on 15% acrylamide denaturing (urea)
Criterion precast gels (Bio-Rad), and then transferred onto Hybond-n + membrane
(Amersham Pharmacia Biotech). The hybridization with [α-32P]ATP was performed
at 42°C in 7% SDS/0.2M Na2PO4 (pH 7.0) overnight. Membranes were washed at
42°C, twice with 2× SSPE [standard saline phosphate/EDTA (0.18 M NaCl/10 mM
phosphate, pH 7.4/1 mM EDTA)]/0.1% SDS and twice with 0.5× SSPE/0.1% SDS.
CCAT2 probes used were as published previously in Hui et al. As loading control we
used 5S rRNA stained with ethidium bromide.
Southern blot
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Mice were screened for the presence of the transgene by Southern blot analysis on
tail DNAs digested with PshA1. Different concentrations of the 4.5kb sequence used
for pronuclear injection were used as the copy number positive controls. Blots were
hybridized with the same CCAT2 DNA fragment reported in Ling et al. Genotyping
was performed on tail DNAs by PCR.
Western blot
Proteins were collected from cultured cells and lysed with RIPA buffer (SIGMA)
freshly supplemented with a complete protease inhibitor cocktail (SIGMA). The
Bradford assay was used to measure protein concentrations. Proteins were
separated on polyacrylamide gel (Bio-rad) electrophoresis and transferred to a 0.2
µm nitrocellulose membrane (Bio-rad). Vinculin was used as loading control and
quantification of protein expression was done with ImageJ. All antibodies were
purchased from Cell Signaling unless mentioned otherwise. The following antibodies
were used for analysis: EZH2, H3K27Me3, Histone H3, GFP, and p27.
In vivo detection of apoptosis via TUNEL assay
Apoptotic cells in bone marrow tissue were detected by terminal deoxynucleotidyl
transferase-mediated dUTP nick-end labeling (TUNEL) staining using an apoptotic
cell detection kit following the manufacturer's directions (Promega, Madison, WI,
USA). Images of the sections were captured using a Nikon 600 microscope (Nikon,
Tokyo, Japan). The apoptotic index was calculated by dividing the number of
TUNEL-positive cells by the total number of cells in the field. Light microscopy was
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used to count the number of TUNEL-positive cells on ten randomly selected fields
for each section.
Alkaline Comet Assay
Freshly isolated bone marrow cells from CCAT2(G/T) and WT mice were subjected
to alkaline comet assay according to the manufacturer’s instructions (catalog #
4250-050-K; Trevigen). Briefly, cells were combined with low melting agarose onto
CometSlides (Trevigen). After lysis, cells were subjected to electrophoresis and
stained with SYBR green. Subsequently, cells were visualized using fluorescent
microscopy (Carl Zeiss, Thornwood, NY). At least 200 comet images were analyzed
for each time point using Comet Score software (version 1.5; TriTek Corp.). The
number of tail-positive cells with small and large nuclei was manually counted by an
examiner blinded to treatment group, and expressed as a percentage of all cells
evaluated. Experiments were repeated in triplicate.
Flow Cytometry analysis
Single-cell suspensions were prepared from bone marrow (from femoral and tibial
bones) by passing cells through pre-separation filters (Miltenyi). Cell numbers were
subsequently counted. Cells were fixed and stained according to standard protocol
for FACS sorting and analysis. Cells were acquired using LSR Fortessa (BD
Bioscience) and analyzed using FlowJo software (Tree Star). Dead cells were
excluded by staining them with Ghost Dye (Tonbo Biosciences). Cell doublets were
excluded from all analyses. Lin− cells were enriched using a Mouse hematopoietic
progenitor cell enrichment kit (Stem Cell Technologies). The antibodies (all from
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eBioscience, Tonbo or Biolegend) conjugated to FITC, APC, APC-Cy7, PE, PE-Cy7,
PercpCy5.5, EFLUOR450, or APC-Cy7 were used for the flow cytometry analysis.
RNA immunoprecipitation
We used the Magna RIP Kit (Millipore) according to the manufacturer's instructions.
Cells were prepared in RIP lysis buffer, and the RNA–protein complexes were
immunoprecipitated with magnetic beads using anti-EZH2 or normal mouse IgG
(control)

(Appendix).

Co-purified

RNA

was

extracted

using

phenol:chloroform:isoamyl alcohol and subjected to reverse transcription and realtime qPCR analysis. B2M was used as a non-target internal control.
GST-MS2 pull-down assay
HEK293 cells were transfected with 2 ug of pMS2-CCAT2 or pMS2, together with 1
ug of pMS2-GST, and total lysates were prepared after 48 hrs of transfection. The
protein-RNA complexes were immunoprecipitated using GSH agarose beads (GE
Healthcare). Co-purified proteins were analyzed by western blot analyses. GST was
used as the internal transfection control.
MicroRNA microarray
After extraction of total RNA using Trizol (Sigma), the RNA samples from bone
marrow cells (n=3 each) were checked for purify and quality via an Agilent
Bioanalyzer before being submitted for human miRNA array (Sanger miRBase v15,
1,087 human miRNAs) analysis. The results of the analysis were used to determine
which miRNAs had significant “fold” differences in expression between WT and
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CCAT2(G/T) mice. The miRNAs with the most significant differences in expression
levels were then chosen for the miRNA target analysis using multiple bioinformatics
prediction tools, including TargetScan 6.2 (http://www.targetscan.org/), PicTar
(http://pictar.mdcberlin.de/),

miRanda

(http://www.microrna.org/),

and

miRDB

(http://mirdb.org/miRDB/).
Clinical samples
CD34+ cells from bone marrow of 80 myelodysplastic syndrome patients and 33
myeloproliferative patients were obtained from MD Anderson Cancer Center tissue
bank. A second set of peripheral blood from 55 myelodysplastic syndrome patients
and 8 normal patient samples were obtained from Romania (University of Medicine
and Pharmacy Iuliu Hatieganu). All samples were collected according to the
institutional policies and obtained following patient’s informed consent. Tissue
samples were obtained from fresh surgical specimens frozen in liquid nitrogen and
stored at −80°C. Data were de-identified prior to any analyses using standard
procedures.
Statistical analysis
For the MDS patient samples, the statistical analyses were performed in R (version
2.14.2). The Shapiro-Wilk test was applied to determine whether data followed a
normal distribution. Accordingly, the t-test or the nonparametric Mann-WhitneyWilcoxon test was applied to assess the relationship between CCAT2 expression
levels and clinical parameters. We investigated the prognostic value of the clinical
and biological variables with metastasis-free survival (MFS) as the end point using
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Cox univariate and multivariate regression analyses. CCAT2 RNA levels were
analyzed as a log-transformed continuous variable and also, for visualization in
Kaplan-Meier survival analysis, as a dichotomized variable based on the median
level of CCAT2 RNA, with the log-rank test used to evaluate differences. Unless
specified otherwise, all data are presented as the mean values ± the standard error
of the mean from at least 3 independent experiments. Two- sided t tests were used
to test the relationships between the means of data sets, and P values indicate the
probability of the means compared, being equal with *P < 0.05, **P <0.01 and ***P
< 0.001. Student’s t tests and analysis of variance were calculated with GraphPad
software. Statistical analyses were performed in R (version 3.0.1) (http:///www.rproject.org/), and

P

values

less

than

significant.
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0.05
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Generation of CCAT2(G/T) transgenic mice
In order to study the consequence of CCAT2 overexpression in vivo, we
generated transgenic mice for each CCAT2 allele (G or T) using random integration
approach in C57Bl6/N background. The human CCAT2 cDNA was expressed under
the control of CAG promoter, which gets expressed ubiquitously in all mice tissues,
along with eGFP fluorescent tag using IRES (internal ribosome entry site) (Figure
8A). All CCAT2(G/T) pups were born at expected frequencies and without any
abnormalities. Pups were screened for presence of the transgene by both PCR and
Southern blot analysis on tail-extracted DNA. For PCR screening, three different
primer pairs were used to detect different products in the inserted transgene. Pups
showing positive detection for all three products were identified as founders (Figure
8B). Five positive founders were identified, G26-0-0, G28-0-0, G31-0-0 (founders
with G allele) and T06-0-0, T12-0-0 (founders with T allele). We also performed
southern blot analysis to confirm insertion of CCAT2 cassette in the mice genome
and to determine to copy number of the insertion. Comparing the band intensity with
the copy number standards, founder 26-0-0 had insertion between 5-10 copies, and
all the other founders between 1-5 copies (Figure 8C). Sanger sequencing
confirmed integration of specific G or T allele in the mouse genome (Figure 8D).
Thus, the genomic DNA of the G mice had only G allele, while T mice only had T
allele, validating the allele-specific CCAT2 transgenic model.
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Figure 8: Generation of CCAT2(G/T) transgenic mice.
(A) The schematic of the CCAT2 vector construct that was integrated in the mice
genome by random integration using pronuclear injection.
(B) PCR on tail genomic DNA from five positive founders detected using three
different primer pairs.
(C) Southern blot analysis using tail genomic DNA from five positive founders to
detect the integration copy number.
(D) Sanger sequencing analysis on tail genomic DNA of CCAT2-G and CCAT2-T
mice.
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The expression of CCAT2 transcript was tested by quantitative PCR with
human specific set of primers previously described in (Ling et al., 2013). We
detected a ten- to twenty-fold increase in CCAT2 expression in different tissues of
the animal including colon compared to their non-transgenic siblings (Figure 9A) by
qRT-PCR. Similar level of overexpression was also detected in the bone marrow
cells o these mice (Figure 9B, 9C). Overexpression of CCAT2 was also confirmed
by in situ hybridization in hematopoietic tissues, including bone marrow cells (BMCs)
(Figure 10A) and spleen (Figure 10B). This level of overexpression mimics what we
previously reported for CCAT2 in colon cancer malignancy (Ling et al., 2013).
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Figure 9: CCAT2 transcript expression in CCAT2 transgenic mice.
(A) CCAT2 expression levels in different organs of CCAT2(G/T) mice in comparison
to non-transgenic WT littermates by Real Time qPCR.
(B) CCAT2 expression levels in bone marrow cells of CCAT2(G/T) mice in
comparison to non-transgenic WT littermates by Real Time qPCR.
(C) CCAT2 expression levels in bone marrow cells of CCAT2(G/T) in comparison to
non-transgenic WT littermates by PCR on cDNA.
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Figure 10: CCAT2 expression in bone marrow and spleen of CCAT2 transgenic
mice.
(A, B) In-situ hybridization was performed using CCAT2-specific probes to detect
expression of CCAT2 lncRNA in bone marrow (A) and spleen (B) of CCAT2(G/T)
mice.
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CCAT2(G/T) mice display bilineage cytopenias
We initially expected to see a colon phenotype by overexpressing CCAT2,
since we previously reported that high CCAT2 predisposes to colon cancer tumors.
However, although CCAT2 was expressed at high levels in the colon, no
macroscopic (n = 54) or histological (n = 22) evidence for colon tumors or early
stage polyps were observed in any adult mouse up to 12 months of age (data not
shown). In contrast, within about 6-9 months of age, CCAT2(G/T) mice showed
clinical signs of a hematological phenotype, predominantly widespread cytopenias.
We monitored the hematological parameters of 6-9 months old WT (n = 20), CCAT2G (n = 21) and CCAT2-T (n = 18) mice and observed that CCAT2(G/T) mice
developed bilineage cytopenias. These mice exhibited significantly low WBC (Figure
11A) and lymphocyte counts (lymphocytopenia, Figure 11B); and minor anemia with
lower red blood counts and hemoglobin levels (data not shown) compared to WT
and

non-CCAT2

expressing

littermates,

a

phenomenon

consistent

with

myelodysplasia and ineffective hematopoiesis. No significant difference was
observed in other hematological parameters including levels of eosinophils,
basophiles, monocytes, reticulocytes, hematocrit, mean platelet volume and mean
corpuscular volume in these mice (data not shown).
Interestingly,

about

40%

of

the

CCAT2(G/T)

mice

exhibited

a

myeloproliferative neoplasm (MPN)-like phenotype compared to WT controls. The
mixed MDS/MPN CCAT2(G/T) mice displayed significantly elevated platelet levels
(Figure 11C) along with other myelodysplastic features (Figure 11D, and E). Both
CCAT2(G) and CCAT2(T) mice were equally susceptible to both MDS- or MDS/MPN	
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like features. These data illustrations that overexpression of CCAT2 induces two
distinct phenotypic manifestations in the BM of mice, suggesting a critical role of
CAT2 in maintenance of homeostasis in hematopoietic stem cells.
We also identified a significant increase in presence of LUCs (large unstained
cells) in the peripheral blood (PB) of CCAT2(G/T) mice (Figure 11F). These are
cells that usually cannot be distinguished according to their staining pattern,
including large atypical lymphocytes and immature blasts. Increase of immature cells
in circulation usually signifies compromised BM function.
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Figure 11: Peripheral complete blood counts (CBC) of CCAT2(G/T) and WT
mice
(A-B) WBCs (A), and lymphocytes (B) in CCAT2-G, CCAT2-T and WT mice.
(D-G) Platelets (D), WBCs (F), and lymphocytes (E) in CCAT2(G/T) mice displaying
MDS-like and MDS/MPN-like phenotype compared to non-transgenic WT
littermates.
(F) Presence of large unstained cells (LUCs) in peripheral blood of CCAT2(G/T)
mice.
The data are presented as ± STD. *P < 0.05, **P < 0.01 and ***P < 0.001.
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Consistent with the complete blood counts, morphological analysis of PB
smears by Hema III stain (modified May Giemsa stain) showed presence of several
aberrant circulating blood cells (Figure 12). We observed poikilocytosis and
anisocytosis (RBCs of abnormal shapes and variable size), including presence of
oddly shaped RBCs such as dacrocytes, knizocytes, teardrops, schistocytes and
echnocytes. An increased numbers of immature polychromatophilic RBCs,
reticulocytes and Howell-Jolly bodies were also noted in circulating PB. In the
myeloid lineage, we observed hypogranularity of neutrophils with abnormal lobation.
These

include

presence

of

pseudo-Pelger-Huet

anomaly,

hypersegmented

neutrophils and ringed neutrophils. In the platelet lineage, we noted megaplatelets
with clustered, atypical granulation in the cytoplasm. Clumped platelets of variable
sizes were also observed in PB smears. Levels of circulating platelets were
significantly increased in PB of MPN-like mice.
Additionally, we also observed presence of immature blasts and unidentified
mononuclear cells in PB. The presence of these immature blasts correlated with the
LUCs detected in PB CBC analysis as shown in Figure 11H. Presence of these
immature cells in circulation could potentially indicate their defective maturation in
the BMCs.
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Figure 12: Peripheral blood smears of WT (i) and CCAT2(G/T) (ii-ix) mice
stained with Hema III stain (modified May Giemsa stain).
Atypical cells belonging to each hematological lineage were observed in the PB of
CCAT2(G/T) mice. The aberrant cells are indicated using arrows and labeled.
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CCAT2(G/T) mice have hyperplasic bone marrows
To identify if the bone marrow of these animals showed signs of dysplasia, we
performed histologic examinations of H&E stained BM sections of CCAT2(G/T) (n =
18) and WT (n = 9) animals at 9 months of age. In contrast with WT-mice, all
CCAT2-G and CCAT2-T mice had increased cellularity of the bone marrow.
However, the hematopoietic hypercellularity was higher in CCAT2-G-mice (average
score 3.3) in comparison with CCAT2-T-mice (average score 2.6).

The

hematopoietic hypercellularity of CCAT2-G and CCAT2-T-mice was mostly due to
the increase number of myeloid (granulopoietic) cells, average score of 2.8 in Gmice and 2.0 in T-mice (Figure 13A). This change is consistent with
myeloid/granulocytic hyperplasia in these mice. Increased erythroid cells were also
observed in 2/9 G-mice and 4/9 T-mice (Figure 13B, C). In addition to granulocytes,
there was increased number of megakaryocytes (megakaryocytic hyperplasia) in 6/9
G-mice

and

5/9

T-mice

with

increased

accumulation

of

atypical

micromegakaryocytes was also observed in these mice (Figure 13D). All
CCAT2(G/T) mice we analyzed showed bone marrow hyperplasia and cytopenias of
at-least one lineage compared to their non-transgenic WT littermates. Both MDSand MPN-like mice showed comparable bone marrow hyperplasia and multi-lineage
defects.

	
  

	
   56	
  

WT

G31-1-24

Normal
trilineage
maturation

Myeloid
hyperplasia

G28-1-22

T05-1-51

Erythroid
hyperplasia

Megakaryocytic
hyperplasia

Figure 13: H&E staining of BM sections of CCAT2(G/T) and WT mice.
Femurs from WT and CCAT2(G/T) mice were fixed in 10% Formalin and paraffin
embedded. H&E staining was performed and these slides were then analyzed for
complete histopathology.
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CCAT2(G/T) mice display splenomegaly and hepatomegaly
Along with BM hyperplasia, several alterations in the hematopoietic organs
were noted in these mice, including splenomegaly and hepatomegaly. The spleen
was frequently enlarged (p < 0.01), sometimes up to five-fold that normal weight
(Figure 14A). The liver was also enlarged markedly in several mice (p < 0.01,
Figure

14B).

Histological

examination

revealed

noticeable

extramedullary

hematopoiesis (EMH) and infiltration of hematopoietic precursor cells, diminishing
the white pulp and other germinal centers (Figure 14C). Additionally, minor EMH
was also observed in organs not commonly associated with EMH, such as liver
(Figure 14D). Extensive EMH accompanied by defects in central hematopoiesis
and bone marrow insufficiency suggests that EMH might be partly compensatory.
Since bone marrow insufficiency with ineffective hematopoiesis, and enlarged EMH
organs are a hallmark of MDS/MPN, we concluded that CCAT2(G/T) mice displayed
MDS or mixed MDS/MPN-like disease.
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Figure 14: CCAT2(G/T) mice display splenomegaly and hepatomegaly.
(A, B) Normalized Spleen (A) and Liver (B) weights of CCAT2(G/T) mice displaying
MDS-like or MDS/MPN-like phenotype compared to WT littermates.
(C) Representative images enlarged spleen and liver in CCAT2(G/T mice with mixed
MDS/MPN-like phenotype.
(D) H&E staining of spleen and liver sections of CCAT2(G/T) and WT mice.
The data are presented as ± STD. *P < 0.05, **P < 0.01 and ***P < 0.001.
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CCAT2 bone marrow cells display dysplastic features
We next obtained BM smears from WT and CCAT2(G/T) mice and stained
them with Hema III (modified May Giemsa stain). In CCAT2(G/T) mice, bone marrow
aspirates showed multilineage proliferative and dysplastic changes (Figure 15).
Presence of immature blast cells were observed in several CCAT2(G/T) mice.
However, the proportion of these immature cells were < 5% in BM, indicating
myelodysplastic changes but no significant progression to leukemias.
Findings included increased presence of hypersegmented neutrophils, and
dysplastic erythroblast precursors. A distinct hyperplasia of the bone marrow,
specifically myeloid hyperplasia was noted. Additionally, we observed remarkable
hyperplasia and aggregates of dysplastic megakaryocytes. Micromegakaryocytes
with decreased ploidy and reduced chromatin, as well as mono- and bi-lobated
megakaryocytes were noticed. In spite of thrombocytopenia in some mice,
megakaryocytic hyperplasia was evident in the marrow aspirates, suggesting
aberrant platelet maturation.
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Figure 15: BM smears from WT and CCAT2(G/T) mice stained with Hema III
(modified May Giemsa stain).
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We then stained BM aspirates for characteristic indicators of MDS. We
observed presence of ring sideroblasts in CCAT2(G/T) mice, a characteristic of
MDS, while none were seen in the WT mice (Figure 16A). However, the prevalence
of these ring sideroblasts was <5% in the BM of CCAT2(G/T) mice. Additionally,
staining with iron showed reduced iron deposition in CCAT2(G/T) mice compared to
WT littermates (Figure 16B), indicating minor anemia as observed from peripheral
blood counts.
The blasts were PAS and myeloderoxidase negative (Figure 16C). Further,
reticulin and trichome staining of the bone marrow biopsies revealed no collagen
deposition or myelofibrosis in these mice (Figure 16D). Collectively, these data
show that CCAT2(G/T) overexpression leads to a disease phenotype resembling
clinical manifestation of mixed MDS/MPN in humans without myelofibrosis.
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Figure 16: CCAT2(G/T) mice display characteristic features of MDS or mixed
MDS/MPN phenotype.
(A, B) CCAT2(G/T) BM smears stained for iron. CCAT2(G/T) (n = 3 for each allele)
mice show presence of ring sideroblasts in their BMs (A). The iron deposition is also
reduced in BM of CCAT2(G/T) mice (n = 6) compared to WT littermates (n = 3).
(C, D) Negative PAS and myeloderoxidase staining in CCAT2(G/T) BM smears (n =
5 for each allele).
(E) Negative reticulin and trichome staining of CCAT2(G/T) BM smears (n = 3 for
each allele).
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Enhanced proliferation and excessive apoptosis of hematopoietic stem and
immature progenitor cells is one of the characteristic features of MDS (REF). In
order to further characterize the phenotype, we stained BM biopsies of CCAT2(G/T)
(n = 6) and WT (n = 3) animals for Ki67 (proliferation marker). We observed a
significant increase in Ki67-positive cells in CCAT2(G/T) mice compared to WT mice
(Figure 17A). Both MDS- and MDS/MPN-like mice displayed similar increase in
proliferation. Next, we performed TUNEL analysis to identify apoptotic cells in BM of
these mice. A significant increase in apoptosis was observed in CCAT2(G/T) mice
(Figure 17B). These data indicate dyregulation in the production and maturation of
hematopoietic cells in the BM of CCAT2(G/T) mice. Figure 17C shows the
quantification of Ki67 and TUNEL staining in the WT and CCAT2 bone marrow
biopsies. This data suggests dysregulation of hematopoietic cell maturation and
maintenance, and might play an important role in bone marrow failure.
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Figure 17: CCAT2(G/T) mice display excessive proliferation and enhanced
apoptosis in BM.
(A) BM sections of CCAT2(G/T) and WT mice were stained with Ki67 marker by
immunohistochemistry (IHC) to detect actively proliferating cells.
(B) TUNEL assay was performed on BM sections from CCAT2(G/T) and WT mice.
(C) Quantification of Ki67 and TUNEL staining in BM sections of CCAT2(G/T) and
WT mice.
The data are presented as ± STD. *P < 0.05, **P < 0.01 and ***P < 0.001.
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CCAT2(G/T) bone marrow cells are genomically unstable
CCAT2 overexpression is associated with genomic instability and an increase
in frequency of chromosomal fusions and aneuploidy (Ling et al., 2013). Since
genomic instability of the bone marrow (BM) cells is an important characteristic of
MDS, it was possible that CCAT2 overexpression could lead to increase in
chromosomal abnormalities and thus contribute to MDS phenotype. To examine this
possibility, metaphase spreads were prepared from bone marrow cells of WT (n = 4)
and CCAT2(G/T) (n = 7) mice and were scored for abnormal mitosis. The BM cells
of CCAT2(G/T) mice showed an increased frequency of cytogenetic aberrations
(Figure 18A), and significant increase in number of cells with breaks and
chromosomal fusions (Figure 18B). Figure 18C shows the different types of
structural anomalies detected in CCAT2(G/T) mice, including chromosomal fusions,
fragments, breaks, and ring chromosomes. Next, in order to detect if there were any
specific recurrent mutations or chromosomal fusions in these BM cells, we
performed karyotyping and SKY (spectral karyotyping) analysis on these mice. No
significant genomic deletions or fusions were detected (Figure 19A, 19B),
suggesting that while the bone marrow cells show chromosomal instability, these
aberrations do not follow a specific pattern of induction. Thus, induction of
widespread genomic instability by CCAT2 might be a key event in initiation of MDS.
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Figure 18: CCAT2(G/T) bone marrow cells are genomically unstable.
Metaphase spreads were prepared from bone marrow cells of WT and CCAT2(G/T)
mice, and were scored for abnormal mitosis.
(A) Quantification of abnormal mitosis in metaphase spreads of WT and
CCAT2(G/T) mice.
(B) Percentage of BMCs showing fusions and breaks in WT and CCAT2(G/T) mice.
(C) Representative images of metaphase spreads from WT and CCAT2(G/T) mice
showing several chromosomal aberrations present in these cells.
The data are presented as ± STD. *P < 0.05, **P < 0.01 and ***P < 0.001.
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B

Figure 19: SKY and Karyotyping analysis on BMCs of CCAT2(G/T) and WT
mice.
(A) Representative image showing SKY analysis on one CCAT2(G/T) mice.
(B) Representative image showing karyotyping analysis on two CCAT2(G/T) mice.
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CCAT2(G/T) bone marrow cells do not show DNA damage
DNA damage is an important phenomenon that induces widespread genomic
instability. Therefore, we sought to directly evaluate and quantify DNA damage in
WT and CCAT2(G/T) BMCs. To this end, we used alkaline comet assay to measure
single- and double-strand breaks in BMCs HSCs from 9-10 months old WT (n = 3)
and CCAT2(G/T) (n = 6) mice. BMCs treated with peroxidase were assayed in
parallel as a positive control. Analysis of Olive moment and percent tail DNA did not
show significant differences between BMCs of WT and CCAT2(G/T) mice (Figure
20A, B). Similar results were also obtained in CCAT2 mice displaying MDS and
MPD phenotypes. These data were verified in six independent experiments.
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Figure 20: CCAT2(G/T) bone marrow cells do not show DNA damage.
Alkaline comet assay was performed on BMCs of WT (n = 3) and CCAT2(G/T) (n =
3 for each allele) mice. Left panel shows representative images of comet. Right
panel is the quantification of three independent experiments showing no significant
difference between CCAT2(G/T) and WT BMCs.
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CCAT2(G/T) mice have stable disease and do not progress to leukemias
We next characterized the CCAT2(G/T) and WT mice at different ages to
monitor the progression of MDS or MDS/MPN in these mice. Peripheral blood
analyses of young (<6 months old), 8/9-months old and older (>15 months old)
detected an increased incidence of MDS/MPN phenotype in these mice with age,
with almost 95% of the older mice analyzed displayed MDS/MPN (n = 8 for each
allele). Early signs of mild hyperplasia were noted in the BM section of young mice
(Figure 21A) which corroborated with mild cytopenias observed in the peripheral
blood (Figure 21B). Interestingly, peripheral blood counts, BM sections, and BM
smears of older mice showed similar widespread hyperplasia and cytopenias
(Figure 21C) as 8/9-months of age as reported above. The data suggested an
increased incidence of megakaryocytic hyperplasia in older CCAT2(G/T)-mice in
comparison with 8/9-month old (Figure 21D) mice. Myeloid and erythroid
hyperplasia were relatively constant in older CCAT2(G/T)-mice in comparison with
8/9-month old CCAT2(G/T)-mice (Figure 21D). Overall, the main phenotype of
myeloid and megakaryocytic hyperplasia in conjunction with various degrees of
erythroid hypoplasia of older mice was still greater than 8/9-month old mice.
Additionally, an increased EMH in the spleen of mice was detected in 2/4 G-mice
and 1/4 T-mice. Increased number of megakaryocytes in spleen were present in 3/4
T-mice and 1/4 G-mice. Taken together, these results from cell blood count,
histology and hematological/cytological examination of bone marrow smears
suggest a progression to mixed MDS/MPN with age, while there was no progression
to leukemia in any of the mice we analyzed.
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Figure 21: CCAT2(G/T) mice display stable disease with age and do not
progress to leukemias.
(A) H&E staining of BM sections of 4-5-months old CCAT2(G/T) (n = 5 for each
allele) and WT mice (n = 5).
(B) Total blood counts for WBCs, lymphocytes and platelets in peripheral blood of 45-months old CCAT2(G/T) and WT mice.
(C) Total blood counts for WBCs, lymphocytes and platelets in peripheral blood of
>15-months old CCAT2(G/T) and WT mice.
(D) H&E staining of BM sections of >15-months old CCAT2(G/T) and WT mice.
The data are presented as ± STD. *P < 0.05, **P < 0.01 and ***P < 0.001.
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CCAT2 induces exhaustion of hematopoietic stem cells
To further characterize the mechanisms underlying aberrant differentiation
and maturation in BM of CCAT2(G/T) mice and given the important role of
hematopoietic stem cell and progenitor cells in induction of ineffective hematopoiesis
and myelodysplasia, we performed flow cytometric analyses on BMCs in
CCAT2(G/T) (n = 8 for each allele) mice compared to age- and sex-matched WT
control (n = 8) mice. Interestingly, the MDS and MDS/MPN-like mice showed
presence of significantly different populations in their BM. The proportion of LSK
(Lin-Sca1+cKit+) cells was significantly decreased in MDS-CCAT2(G/T) mice, while
no significant alteration was observed in MDS/MPN-CCAT2(G/T) mice compared to
WT mice (Figure 22A).
Correspondingly, the percentage of long-term HSCs (LT-HSCs, defined by
Lin-c-Kit+Sca-1+CD34loCD135lo population), short-term HSCs (ST-HSCs, defined by
Lin-c-Kit+Sca-1+CD34hiCD135lo population) and multipotent progenitor cells (MPPs,
defined by (Lin-c-Kit+Sca-1+CD34hiCD135hi) were also significantly decreased only in
MDS-CCAT2(G/T) as compared to MDS/MPN-CCAT2(G/T) and WT mice (Figure
22B).
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Figure 22: CCAT2 induces exhaustion of hematopoietic stem cells
(A) Representative flow scatters of BMCs from WT and CCAT2(G/T) mice with
distinct MDS-like and MDS/MPN-like profiles showing percentage of LSK HSCs, STHSCs, LT-HSCs and MPPs using HSC specific markers.
(B) Total number of LSK HSCs, ST-HSCs, LT-HSCs and MPPs cells in CCAT2(G/T)
mice with distinct MDS-like and MDS/MPN-like profiles.
The data are presented as ± STD. *P < 0.05, **P < 0.01 and ***P < 0.001.
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Among the lineage positive cells, the percentage of immature B cells (defined
by B220+IgM-) was significantly reduced in CCAT2-MDS mice compared to WT
controls and MDS/MPN-CCAT2(G/T)

mice (Figure 23). Paired with lower RBC

peripheral blood levels, this suggests a block in differentiation to mature erythroid in
the blood. Conversely, we noted a distinct infiltration of CD4+/CD8+ T cells in the
BM of MDS/MPN-CCAT2(G/T) mice (Figure 24A). The clonal expansion was more
evident in CCAT2-T-MDS/MPN mice (Figure 24B), suggesting that T allele might be
more important in expansion of CD8+ T cells. The flow cytometry data highlight the
two distinct phenotypes induced in CCAT2(G/T) mice, suggesting an important role
of CCAT2 in regulating the HSC pool, which might in turn alter the differentiation
efficiency of remaining progenitor cells in mice.
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Figure 23: Immature B cells in bone marrow of CCAT2 mice
(A) Representative flow scatters of BMCs from WT and CCAT2(G/T) mice with
distinct MDS-like and MDS/MPN-like profiles showing percentage of immature B
cells using specific markers.
(B) Percent Immature B cells in CCAT2(G/T) mice with distinct MDS-like and
MDS/MPN-like profiles.
The data are presented as ± STD. *P < 0.05, **P < 0.01 and ***P < 0.001.
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Figure 24: Infiltration of activated T cells in bone marrow of CCAT2 mice
(A) Representative flow scatters of BMCs from WT and CCAT2(G/T) mice showing
an infiltration of CD4+/CD8+ T cells in MDS/MPN-like mice and CD8+ T cells
specifically in CCAT2-MDS/MPN-T mice.
(B) Percent CD4+/CD8+ (left panel) and CD8+ (right panel) T cells in CCAT2(G/T)
mice with distinct MDS-like and MDS/MPN-like profiles.
The data are presented as ± STD. *P < 0.05, **P < 0.01 and ***P < 0.001.
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To verify the expression of B and T cells in BM, we stained BM sections of
WT and CCAT2(G/T) mice for markers of B (CD20) and T (CD3) cells. We detected
a remarkable increase in CD20+ immature B-cell precursors in the BM sections of
CCAT2-MDS/MPN-like mice but not CCAT2-MDS mice as compared to WT mice.
Additionally, presence of CD3+ immature T cells was also specifically increased in
CCAT2-MDS/MPN mice only. These data confirm our flow cytometry data and
suggest defective maturation and clonal expansion of the T-lymphocytes (Figure
25).
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Figure 25: Immature B cells and activated T cells in bone marrow of CCAT2
mice
Immunohistochemical stainings of CD3 (upper panel) and CD20 (lower panel) in BM
sections of WT and CCAT2(G/T) mice with distinct MDS-like and MDS/MPN-like
features.
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In vitro hematopoietic stem cell assay demonstrated a significant decrease in
colony-forming capabilities of HSCs from CCAT2 mice (Figure 26A). HSCs from
both CCAT2-MDS and CCAT2-MDS/MPN mice showed similar reduction in colony
formation, suggesting that the HSCs from CCAT2 mice have compromised
differentiation. Serial re-plating assay on HSCs from CCAT2-MDS and CCAT2MDS/MPN revealed a remarkable decrease in re-populating efficiency of CCAT2HSCs in vitro (Figure 26B). These data suggest a significant alteration in the selfrenewing and differentiation efficiency of HSCs from CCAT2(G/T) mice.
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Figure 26: CCAT2 induces exhaustion of hematopoietic stem cells in vitro
(A) In vitro colony formation assay in methylcellulose was performed using total
BMCs from WT and CCAT2(G/T) mice. The graph is the average of three
independent experiments.
(B) Total BMCs from WT and CCAT2(G/T) mice were subjected to serial re-plating
analysis. The graph is the average of three independent experiments.
The data are presented as ± STD. *P < 0.05, **P < 0.01 and ***P < 0.001.
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CCAT2 regulates EZH2 expression in an allele specific manner
To determine the mechanism by which CCAT2 induces genomic instability
and myelodysplasia, we screened for several genes that have been previously
reported to induce myelodysplasia as potential targets of CCAT2. Interestingly,
EZH2 was downregulated in the BMCs of CCAT2(G/T) mice compared to WT
littermates (Figure 27A). EZH2 downregulation was observed in both MDS only and
MDS/MPD mice. While EZH2 is frequently overexpressed and considered to be an
oncogene in cancers; nevertheless, EZH2 is considered as a candidate tumor
suppressor gene in MDS/MPN (Ernst et al., 2010). 10% of MDS show loss-offunction mutations in EZH2, and these mutations are associated with poor survival
(Ernst et al., 2010). Ezh2 loss has also been reported to induce development of
myelodysplastic syndrome in vivo, but attenuates its predisposition to leukaemic
transformation (Muto et al., 2013; Sashida et al., 2014). In CCAT2(G/T) mice, EZH2
and H3K27Me3 reduction was observed in hematopoietic stem and progenitor cells
(HSPCs) as well as lineage positive bulk cells (Figure 27B), suggesting that CCAT2
might induce alteration in EZH2 levels in the HSC compartment. Next, we wanted to
determine if EZH2 expression was downregulated pre- or post-transcriptionally.
Using qRT-PCR analysis, we found that EZH2 transcripts were not significantly
downregulated in these CCAT2(G/T) mice (Figure 27C), suggesting a posttranscriptional mechanism of expression levels.
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Figure 27: EZH2 is downregulated in CCAT2(G/T) mice
(A, B) Western blot analysis for EZH2 was performed on total BMCs (A) or enriched
hematopoietic stem and progenitor cells (HSPCs) from WT and CCAT2(G/T) mice.
(B) Real time qPCR analysis was performed on total BMCs from WT and
CCAT2(G/T) mice. The graph is the average of three independent experiments.
The data are presented as ± STD. *P < 0.05, **P < 0.01 and ***P < 0.001.
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In order to determine if the downstream pathway of EZH2 was affected, we
performed western blot analysis for H3K27Me3 (histone trimethylation at lysine 27),
a primary function of EZH2. A corresponding decrease in global H3K27Me3 levels
was observed in these mice (Figure 28A). Since p21 is one of the most important
trimethylation targets of EZH2, we checked for p21 levels in these mice.
Consequently, an increase in p21 was also observed (Figure 28B). Since
maintenance of gene expression via histone trimethylation by EZH2 is an important
event in hematopoietic stem cells, we next determined if this phenomenon was
affected in CCAT2(G/T) mice. We observed a corresponding decrease in
H3K27Me3 levels in the stem cells (Figure 28C). This indicates a global gene
expression dysregulation in the hematopoietic stem cells in CCAT2(G/T) mice.
Based on these data, we concluded that EZH2 expression levels and its functional
activity were downregulated in CCAT2(G/T) mice, and this was true in both MDS-like
and MDS/MPN-like CCAT2(G/T) mice.
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Figure 28: EZH2 functional activity is compromised in CCAT2(G/T) mice
Western blot analysis for H3K27Me3 (A) and p21 (B) levels was performed on total
BMCs or enriched hematopoietic stem and progenitor cells (HSPCs, C) from WT
and CCAT2(G/T) mice.
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To determine the mechanism by which CCAT2 regulates EZH2 expression,
we performed microRNA microarray on the BMCs from age- and sex-matched WT
(n = 3) and CCAT2 (n = 6) BMCs. Microarray analysis identified 92 miRNAs that
were dysregulated in either CCAT2-G or –T mice compared to WT control mice.
Interestingly, using Ingenuity pathway analysis, one of the top significant molecular
and cellular functions associated with these potential CCAT2-regulated miRNAs
included a subset important in hematological malignancies (data not shown). We
validated the expression of some of the potential miRNAs in BMCs of CCAT2(G/T)
and WT mice, and identified miR-26a, miR-26b, miR-21, miR-150, and miR-155 to
be significantly upregulated in CCAT2-G mice, while miR-130c to be significantly
upregulated in both CCAT2-G and -T mice (Figure 29A). We next used multiple
miRNA target prediction programs (RNA22, TargetScan, miRanda, microT, and
PicTar) to determine whether these miRNAs could potentially target EZH2.
Interestingly, we identified miR-26a, miR-26b, miR-155, and miR-150 were either
already reported or predicted to target EZH2 (Figure 29B). In order to further identify
the role of CCAT2 in these interactions, we determined expression levels of these
miRNAs in CCAT2-overexpressing SET2 cells (Figure 29C). Interestingly, only
CCAT2-G overexpressing cells showed a significant increase in expression levels of
these miRNAs, emulating what we observed in the BMCs of WT and CCAT2-G
mice. These data suggests that CCAT2-G regulates EZH2 expression primarily
through regulation of target miRNAs.
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Figure 29: EZH2 targeting miRNAs are upregulated in CCAT2-G mice
Expression levels of miR-26a and miR-26b, miRNAs that target EZH2, were
analyzed using Taqman real time qPCR in CCAT2(G/T) BMCs (A), CCAT2overexpressing HEK293 cells (B) and CCAT2-overexpressing SET2 cells (C).
The graph is the average of three independent experiments. The data are presented
as ± STD. *P < 0.05, **P < 0.01 and ***P < 0.001.
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On performing CCAT2-EZH2 sequence analysis, a potential EZH2 binding
motif was identified on the CCAT2 transcript. RNA-pulldown assay using MS2
vectors containing CCAT2- G or T allele successfully identified EZH2 to interact
preferentially to CCAT2-T compared to empty MS2 or CCAT2-G transcript (Figure
30A). To further evaluate the binding affinity of EZH2 to a single nucleotide on
CCAT2, we repeated the RNA-pulldown assay using MS2 vectors with mutated SNP
into an A or C, and confirmed that EZH2 preferentially binds to only the CCAT2-T
transcript (Figure 30B). RNA-Immunoprecipitation (RIP) assay using EZH2
antibodies successfully detected CCAT2 transcript in HEK293 stable clones
overexpressing the CCAT2-T allele, but not from HEK293-CCAT2-G or the empty
cells (Figure 30C). To confirm this interaction in vivo, we performed RIP on BMCs
from CCAT2-G, -T and WT mice using EZH2 antibodies. qPCR amplification
confirmed interaction with EZH2 in CCAT2-T mice but not in WT or CCAT2-G mice
(Figure 30D). These data confirmed that EZH2 preferentially binds to the CCAT2 in
an allele-specific manner.
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CCAT2-G
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Figure 30: EZH2 specifically binds to CCAT2-T lncRNA
(A, B) RNA pull-down analysis was performed in vitro using GST-fusion plasmids
expressing different CCAT2 alleles. Western blot analysis was performed on the
pull-down lysate. TCF7L2 was used as a positive control. GST-MS2 was used as a
loading control.
(C, D) RNA-Immunoprecipitation analysis was performed on CCAT2-overexpressing
HEK293 cells (C) or total BMCs from CCAT2(G/T) and WT mice (D). Real time
qPCR analysis was performed to identify CCAT2. B2M was used a non-target
internal control. The experiment was repeated three times.
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Next, to identify how CCAT2 regulates EZH2 expression, we performed
cycloheximide chase assay on CCAT2-overexpressing HEK293 stable clones. As
shown in Figure 31, 10 hours after cycloheximide treatment, the levels of EZH2
reduced to 65% compared to its original amount only in CCAT2-T clones, while no
significant alteration was noted in CCAT2-G or empty clones. This data was
confirmed in three independent experiments. Together these experiments
demonstrate that CCAT2 regulates the stability of EZH2 in an allele-dependent
manner.
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Figure 31: CCAT2-T lncRNA reduces the stability of EZH2 protein
CCAT2-overexpressing HEK293 cells were treated with cycloheximide and lysates
were collected every two hours till 10 hours. Western blow analysis was performed
to determine the stability of EZH2 protein in these cells. Right panel shows the
average of three independent experiments.
The data are presented as ± STD. *P < 0.05, **P < 0.01 and ***P < 0.001.
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CCAT2 is overexpressed in human MDS patients
To access the relevance of these findings to humans, we examined CCAT2
expression in CD34+ cells from the bone marrow biopsies of MDS of all subtypes
including MDS that had transformed to AML. We identified significantly higher
CCAT2 expression in the MDS patients (n = 70) as compared to healthy volunteers
(n = 5) (Figure 32A). CCAT2 overexpression was observed in both high risk and low
risk patients (Figure 32B), while no significant difference in CCAT2 expression was
noted between groups of different risks classified according to the IPSS system
(Figure 32C). No significant difference in CCAT2 expression was detected between
MDS patients presenting different cytogenetic aberrations (data not shown).
Additionally, CCAT2 overexpression was not correlated with survival advantage in
MDS patients. We next compared CCAT2 expression levels in patients with only
MDS to those that progressed to AML. Interestingly, patients with AML had
significantly lower expression of CCAT2 as compared to patients with MDS (Figure
32E). This is in agreement with our initial observation that CCAT2 levels decreased
with increased risk of AML progression. Taken together, these data indicate that
CCAT2 plays a critical role in initiation of MDS, while it doesn’t play an important role
in its progression to AML.
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Figure 32: CCAT2 expression in MDS patient samples
qRT-PCR analysis for CCAT2 expression in CD34+ cells from BM biopsies of MDS
patients.
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CHAPTER IV: Discussion
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In this study, we demonstrate that overexpression of CCAT2 lncRNA alters
hematopoiesis and induces spontaneous de novo MDS- or mixed MDS/MPN-like
syndrome which closely emulates the human diseases. We generated a whole-body
transgenic mouse in order to determine the organ, and consequently the disease
phenotype most sensitive to CCAT2 overexpression. We identified that one of the
most critical roles of CCAT2 is in the regulation of hematopoietic stem cells. We
initially expected to see a colon phenotype by overexpressing CCAT2, since we
previously reported that high CCAT2 predisposes to colon cancer tumors.
Interestingly we observed that CCAT2 plays an important role in maintenance of
hematopoietic homeostasis, regulating the self-renewal and differentiation capacity
of hematopoietic stem cells. This is the first report describing that overexpression of
a lncRNA spontaneously induces myelodysplasia or myeloproliferation. Deletion of
Xist lncRNA has been previously reported to develop an aggressive phenotype
comprising mixed myelodysplastic and myeloproliferative neoplasm, leukemia,
primary myelofibrosis and histiocytic sarcoma (Yildirim et al., 2013). However, our
CCAT2 mice models can serve as a robust model for studying initiation of de novo
MDS/MPN that does not progress to secondary AML and as a pre-clinical model for
evaluation of new therapies for MDS. It has high translational potential as CCAT2
can be developed into a novel intervention target for MDS/MPN therapy.
We report here that overexpression of CCAT2 at clinically relevant levels
induces two distinct MDS- or MDS/MPN-like features in a mouse model. In this
study, we generated two separate transgenic mice lines, expressing each allele of
CCAT2 transcript (G or T). Interestingly, we observed that both alleles
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spontaneously induced myelodysplastic features in the mice, with distinct MDS or
MDS/MPN-like characteristics. However we noted subtle allelic preferences in the
prevalence of MDS- or MDS/MPN-features in CCAT2 mice. Approximately 55% of
CCAT2-T mice developed MDS-like features, while almost 60% of CCAT2-G mice
developed MDS/MPN-like phenotype. Our data indicates that overexpression of
CCAT2 transcript, and not essentially its allelic distribution, is important in initiation
of MDS or MDS/MPN-like features. Instead, CCAT2 alleles G or T play an important
role in regulating the downstream targets of CCAT2, since CCAT2-G and CCAT2-T
have different secondary structures. Thus, further characterization of these mice will
help us understand the role of a SNP in regulating the factors important in initiation
of MDS and MDS/MPN. Additionally, this is the first study providing in vivo evidence
of the role of rs6983267 SNP in predisposition of MDS and mixed MDS/MPN. A
large-scale prospective study to further illustrate the relevance of this SNP in MDS
and MDS/MPN will enhance our understanding of the biology of these diseases.
The CCAT2 mice displaying only MDS-like and mixed MDS/MPN-like
phenotype show significantly different characteristics. CCAT2-MDS-like mice display
predominant leukopenia, minor anemia, multilineage BM hyperplasia, exhaustion of
hematopoietic stem cells, and increased proliferation and concurrent apoptosis of
maturing cells in bone marrow; characteristic features of MDS in humans.
Conversely,

CCAT2-MDS/MPN-like

mice

show

distinctive

thrombocytosis,

splenomegaly, and hepatomegaly in addition to other characteristic BM dysplastic
features similar to MDS. An important distinguishing criterion is rampant peripheral
thrombocytosis in MDS/MPN-like mice. This might be a manifestation of the
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widespread megakaryocytic dysplasia observed in both MDS- and MDS/MPN-like
mice.

Megakaryocytic

dysplasia

leads

to

thrombocytopenia

in

MDS-

but

thrombocytosis in mixed MDS/MPN, suggesting that CCAT2 play a critical role in
regulation of megakaryocytic differentiation. One additional difference is that while
BM of CCAT2-MDS/MPN mice are hyperplasic, they do not show exhaustion of
hematopoietic stem cells, suggesting an imbalance in hematopoietic homeostasis.
One potential explanation for the distinct BM presentation between these mice could
be that CCAT2 induces global chromosomal instability in the HSCs, altering the fine
balance between proliferation and apoptosis in BMCs.
An interesting observation was the distinct infiltration of CD4+/CD8+ T cells in
the BM of CCAT2-MDS/MPN mice. There is accumulating evidence associating
MDS to autoimmune disease, and that the bone marrow failure in MDS is primarily
mediated via autoimmune myelosuppression from T lymphocytes (Chamuleau et al.,
2009; Epperson et al., 2001; Mailloux and Epling-Burnette, 2013; Rosenfeld and
List, 2000). It is speculated that this is an important component in the marrow failure
that may respond to immunosuppressive treatment with antithymocyte globulin or
cyclosporine (Epperson et al., 2001). In CCAT2 mice, the clonal expansion was
more evident in CCAT2-T-MDS/MPN mice, suggesting that T allele might be more
important in expansion of CD8+ T cells. The CCAT2 model might help address
important questions about the role of autoimmunity in MDS/MPN.
We have previously reported that one of the primary mechanisms of CCAT2’s
oncogenic behavior in MSS colorectal cancer is through initiation of global genomic
instability (Ling et al., 2013). Our study reproduces this observation in vivo, since
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CCAT2 transgenic mice show global chromosomal instability in their BMCs. While
the underlying pathogenesis of MDS and MDS/MPN is unclear, it is thought that
clonal expansion of somatically mutated unstable hematopoietic stem and progenitor
cells play a critical role in it (Woll et al., 2014). Cytogenetic abnormalities in MDS
arise primarily from accumulation of genomic damage, failure to repair such
damage, or both. Our study demonstrates that overexpression of CCAT2 is sufficient
to induce de novo myelodysplasia and myeloproliferative alterations. Our data
suggests that higher CCAT2 levels lead to widespread accumulation of genetic
alterations, manifested by recurrent chromosomal breaks and fragmentation, which
in turn drives myelodysplasia. However, we did not detect any specific translocations
or deletions in the BMCs of these mice as evidenced by SKY and G-banding
analyses, suggesting that CCAT2 potentially regulates ubiquitous cellular processes
that maintain global genomic integrity.
In

order

to

determine

the

mechanism

by

which

CCAT2

induces

myelodysplasia, we screened for several genes that have been previously reported
to induce myelodysplasia as potential targets of CCAT2. We identified EZH2 to be
one of the potential downstream effectors of CCAT2. EZH2 protein levels were
significantly downregulated in the HSCs of both CCAT2-MDS as well as CCAT2MDS/MPN mice, suggesting that decline in EZH2 levels might be responsible for the
extensive dysregulation we observed in BMCs. Our data is strongly supported by
multiple studies implicating EZH2 in both MDS and mixed MDS/MPN (Ernst et al.,
2010; Muto et al., 2013; Sashida et al., 2014). While EZH2 is frequently
overexpressed and considered to be an oncogene in cancers; nevertheless, EZH2 is
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considered as a candidate tumor suppressor gene in MDS/MPN. 10% of MDS show
loss-of-function mutations in EZH2, and these mutations are associated with poor
survival (Ernst et al., 2010). Additionally, EZH2 dysregulation has also been shown
to promote genomic instability by altering the global epigenetic landscape in tumor
cells (Gonzalez et al., 2011). Sashida et al (Sashida et al., 2014) reported that EZH2
loss is enough to induce MDS in vivo; while other studies report its concomitant loss
with Tet2 (Muto et al., 2013) also significantly promotes MDS initiation. Conversely,
(Herrera-Merchan et al., 2012) reported that ectopic re-expression of EZH2 induced
mixed MDS/MPN-like phenotype in conditional knock-in murine models. While
contrasting data exist about the loss or gain of EZH2 induces MDS or MDS/MPN-like
features, it is evident that epigenetic dysregulation in the HSCs compartment by
EZH2 plays a critical role in regulating their homeostasis.
Interestingly, multiple studies have reported that EZH2 loss actively alleviates
the leukemogenic transformation capacity of HSCs (Sashida et al., 2014; Tanaka et
al., 2012). This is further supported by the information that EZH2 loss-of-function
mutations are rare in AML (Ernst et al., 2010). This data is important since all
CCAT2 mice display stable disease with age and do not progress to AML even after
30 months of age. This suggests that alteration in CCAT2 expression levels might be
an early genetic event that is essential in the initiation of myelo-alteration, but would
typically require other co-occurring alterations (genetic “hits”) to progress to AML.
Thus, this mouse model could be used to study the factors that are critical in
transforming MDS or MPN to AML.
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Another surprising finding of the study is the allele specific regulation of EZH2
by CCAT2. We report that CCAT2-G transcript potentially targets EZH2 via posttranscriptional regulation by miR-26a and miR-26b, microRNAs previously reported
to target EZH2 (Dang et al., 2012; Lu et al., 2011; Wong and Tellam, 2008). On the
other hand, CCAT2-T transcript directly binds to the EZH2 protein and reduces its
stability. This is the first study reporting the role of a SNP in altering the target profile
of a lncRNA. We hypothesize that the differences in the secondary structures of
CCAT2 at the SNP locus potentially plays a role in this. More detailed studies are
required to identify the how CCAT2-G regulates microRNA expression. Additionally,
identification of the mechanism by which CCAT2-T destabilizes EZH2 protein will
shed light on lncRNA-protein interaction.
We report for the first time that CCAT2 lncRNA in significantly upregulated in
the CD34+ BMCs of MDS patients compared to normal healthy individuals.
Interestingly, CCAT2 expression levels were significantly lower in MDS patients that
progressed to AML, clearly differentiating the two groups. This observation is in
congruence with the CCAT2 mice, since they also do not progress to AML. Thus,
CCAT2 can be potentially used as a prognostic biomarker to identify MDS patients
susceptible to AML progression. Further characterization of these mice will help
understand the factors that govern initiation of MDS/MPN and its further progression
to AML. Interestingly, trisomy 8, presence of three copies of chromosome 8, is an
important genetic aberration present in 10 – 15% MDS patients, including about 5%
patients with +8 as the sole aberration (Paulsson and Johansson, 2007).
Additionally, in MDS/MPN-U patients, trisomy 8 is one of the most prevalent sole
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aberrations (15%) present (DiNardo et al., 2014). Since CCAT2 is transcribed from
the highly unstable 8q24.21 region, genomic amplification in trisomy 8 can be one of
the potential explanations for CCAT2 overexpression. Further studies are warranted
to determine the mechanism of CCAT2 overexpression in MDS and MDS/MPN
patients.
MDS are a group of heterogeneous clonal stem cell disorders that are
primarily characterized by ineffective hematopoiesis and prevalent cytopenias
(Rosenfeld and List, 2000). The main prognostic factors for diagnosis of MDS
include the number and severity of cytopenias, percentage of blasts in the marrow,
and incidence of cytogenetic abnormalities, allowing their classification into different
subgroups according to their risk of progression to acute myeloid leukemia and
predicted survival (Tefferi and Vardiman, 2009). MDS is predominantly a disease of
the elderly. About 86% of patients with MDS are diagnosed after the age of 60
years, with a median age of diagnosis being 76 years (Tefferi and Vardiman, 2009).
Between 2006 and 2010, there were about 15,000-20,000 new cases of MDS per
year in the United States. Despite this growing prevalence, the underlying
mechanisms that induce de novo MDS remains poorly understood. Mixed MDS/MPN
(unclassifiable), on the other hand, are patients at diagnosis with clinical,
morphologic and laboratory features which overlap both those of MDS and MPN
features, and that do not satisfy criteria for chronic myelomonocytic leukemia
(CMML), atypical chronic myeloid leukemia BCR-ABL1 negative (aCML), or juvenile
myelomonocytic leukemia (JMML). MDS/MPN-U is a rare diagnosis, making up less
than 5% of all myeloid disorders. MDS/MPN-U is formally defined as “patients with
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no preceding history of MDS or MPN, no recent cytotoxic growth factor therapy, no
Philadelphia chromosome, BCR-ABL1 fusion gene, PDGFRA, PDGFRB or isolated
del(5q), t(3;3)(q21;q26) or inv(3)(q21q26), and with dysplastic features in ≥1
hematopoietic cell line, <20% blasts in the blood and bone marrow, prominent
myeloproliferative features (i.e., platelet count ≥450×109/L or white blood cell count
≥13×109/L, with or without splenomegaly); or de novo disease with mixed
myeloproliferative and myelodysplastic features which cannot be assigned to any
other category of MDS, MPN or of MPS/MPN” (quoted from DiNardo et al., 2014).
Consequently, no standard prognostic or treatment algorithms for MDS/MPN-U exist.
Current therapeutic options for MDS or MDS/MPN are largely dependent on
the risk stratification of the patients (Tefferi and Vardiman, 2009). Only three drugs
have been approved in the United States specifically for MDS, and second-line
therapies do not exist beyond clinical trials or supportive care. Allogeneic
hematopoietic stem cell transplant (HSCT) is the only potentially curative therapeutic
option. However, approximately three-quarters of the MDS patient population are
ineligible for HSCT due to older age and poor overall health status (Tefferi and
Vardiman, 2009). While about 30% patients that progress to AML are typically
treated with hypomethylating agents or considered for allogeneic stem-cell
transplantation, the remaining 70% lower-risk patients are usually offered less
aggressive therapies, mainly including transfusion support, or simply supportive
symptomatic care (Bejar and Steensma, 2014). Thus, improved understanding of the
factors that contribute to initiation of MDS and mixed MDS/MPN and accurate
identification of patients with worse prognosis and higher risk of progression to AML
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could have important implications for development of novel risk-appropriate
therapies.
Thus, in conclusion, we propose that constitutive overexpression of CCAT2
leads to global genetic instability that drives the spontaneous initiation of de novo
MDS and MDS/MPN (Figure 33). According to our model, CCAT2 induces this
effect partially by regulating the EZH2 protein levels in an allele specific manner, and
thus altering the epigenetic landscape of the hematopoietic stem cells. Our study
improves our understanding of MDS and MDS/MPN biology and further expounds
the role of lncRNAs in tumorigenesis. The CCAT2-G/T model provides a unique
opportunity to study the similarities and differences in the pathogenesis of MDS and
mixed MDS/MPN diseases. This mouse model may be useful as a pre-clinical tool to
test potential therapies for MDS as well as mixed MDS/MPN. Further, CCAT2 can
be developed as a potential therapeutic target for management of MDS and
MDS/MPN. Further studies are required to clearly define the potential roles and
implications of CCAT2 in myeloid malignancies.
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Figure 33: Graphical model of initiation of MDS and MDS/MPN by CCAT2
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Conclusion
The discovery of functional non-protein-coding RNAs (ncRNAs, that do not
codify for proteins) in the last decade has initiated a shift in the paradigms of cancer
biology and has profoundly influenced our understanding of molecular genetics.
Long non-coding RNAs (lncRNAs) form the largest part of the mammalian noncoding transcriptome and control gene expression at various levels including
chromatin modification, transcriptional and post-transcriptional processing. Although
the underlying molecular mechanisms are not yet entirely understood, lncRNAs are
implicated in initiation and progression of several cancers. Identification of novel
lncRNAs and their roles in regulation of protein-coding genes will provide vital
information about the processes that drive tumorigenesis.
CCAT2 is a novel lncRNA that spans the highly conserved 8q24 region
associated with increased risk for various cancers. CCAT2 has been shown to play
an important role in inducing chromosomal instability and supporting cell proliferation
and cell cycle arrest. CCAT2 lncRNA is overexpressed in colorectal, breast, and
lung adenocarcinomas. However, a causal role of CCAT2 in initiation of
tumorigenesis and the importance of G/T SNP in CCAT2-induced phenotype still
remains to be resolved. In this study, we generated transgenic mice for each CCAT2
allele using random integration approach to elucidate the role of CCAT2 and its
specific alleles (G/T) in regulation of cellular processes that drive spontaneous
tumorigenesis.
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In this study, we identified that CCAT2 plays an important role in regulation of
normal hematopoiesis. Constitutive in vivo overexpression of each CCAT2 transcript
in the mice resulted in spontaneous induction of widespread pancytopenias with
splenomegaly and hepatomegaly. CCAT2(G/T) BM biopsies displayed severe
myeloid or erythroid hyperplasia, and dysplastic megakaryocytic proliferation, along
with enhanced proliferation and excessive apoptosis. Interestingly, we identified two
distinct phenotypes in CCAT2(G/T) mice with equal prevalence of MDS or mixed
MDS/MPN. This suggests that CCAT2 overexpression might affect regulation of
hematopoietic stem cells, disturbing their self-renewal or maturation capacity, and
subsequently resulting in BM failure. Percentage of HSPCs was significantly
reduced in BM of MDS mice, with increased presence of immature erythroid blasts
and granulocyte-macrophage progenitors suggesting a block in differentiation.
HSPCs of CCAT2(G/T) mice also showed increased frequency of cytogenetic
aberrations, including breaks and chromosomal fusions. However, these mice don’t
develop sAML, suggesting CCAT2 is critical in initiation of MDS. Microarray
expression profiling of CCAT2(G/T) HSPCs revealed enrichment of pathways
associated with epigenetic regulation, chromosomal instability and cell cycle
regulation. We further identified significantly higher CCAT2 expression in the MDS
patients as compared to healthy volunteers. Patients with sAML had significantly
lower expression of CCAT2 as compared to patients with only MDS.
Deciphering the role of CCAT2 in spontaneously induced myelodysplasia and
cytopenias will help us further characterize the poorly understood MDS/MPN
phenotype. CCAT2 mice can serve as a robust model for studying initiation of de
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novo MDS/MPN that does not progress to secondary AML, and as a pre-clinical
model for evaluation of new therapies for MDS. It has high translational potential as
CCAT2 can be developed into a diagnostic and prognostic marker, as well as a
novel intervention target for MDS therapy.
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Future directions
This project provided basis for a number of future studies. Detailed understanding
of function and regulation of CCAT2(G/T) mice will help understand the factors
involved in initiation of MDS, and thus provide better options for therapeutic
intervention.
Further investigation on mechanism of CCAT2 in driving cellular process
important in initiation of MDS vs MDS/MPN and its progression to AML
In order to identify the genetic regulators of MDS and mixed MDS/MPN in CCAT2
mice, an unbiased Affimetrix cDNA microarray and antisense oligomer-RNA-protein
pull-down experiments can be performed on the BM cells of CCAT2(G/T) in
comparison to WT mice, to obtain a list of differentially expressed genes when
CCAT2 is overexpressed. This will provide more information on the most impactful
downstream genes and pathways regulated by CCAT2. Additionally, comparison
between MDS-like and mixed MDS/MPN-like mice will yield useful information on the
genetic differences in these two indications. This can also be useful to identify novel
therapeutic targets specific for each disease. Finally, comparison between CCAT2-G
and CCAT2-T mice will also provide important information on the functional
significance of the SNP in predisposition to MDS and mixed MDS/MPN.
CCAT2 as a prognostic biomarker for MDS and its progression to AML
We report that CCAT2 expression levels were significantly upregulated specifically in
MDS patients that do not progress to sAML. This could be very important in order to
identify patients that are susceptible to AML progression. For this purpose, CCAT2
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expression levels will need to be determined in a larger cohort of MDS and mixed
MDS/MPN patients, spanning multiple institutions in several countries. Additionally,
Sanger sequencing can be performed to determine the status of rs6983267 SNP at
the genomic and RNA level in these patients to further understand the significance
of the SNP in MDS and MDS/MPN.
CCAT2 as a potential therapeutic target in MDS and mixed MDS/MPN
Our study reported that ectopic overexpression of CCAT2 in vivo leads to
spontaneous induction of MDS and mixed MDS/MPN-like diseases. Our study
provides strong evidence implicating the importance of CCAT2 in these diseases,
providing a basis for its development into a potential therapeutic option for treatment
of MDS and/or MDS/MPN. In vivo treatment of these mice with LNA (Locked nucleic
acid)-based anti-sense CCAT2 oligomers can be performed to determine if targeting
CCAT2 can help in reversal of the MDS or MDS/MPN phenotype. An important
therapeutic end point of this experiment would be to rescue the self-renewal capacity
of HSCs and promote their normal maturation into adult hematopoietic stem cells.
Additionally, CCAT2-anit-sense-LNAs can also be administered in conjunction with
lenalidomide or azacitidine to see if combination therapy can afford improved
therapeutic efficacy.
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